<SEC-DOCUMENT>0001193125-15-269981.txt : 20150730
<SEC-HEADER>0001193125-15-269981.hdr.sgml : 20150730
<ACCEPTANCE-DATETIME>20150730114933
ACCESSION NUMBER:		0001193125-15-269981
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150731
FILED AS OF DATE:		20150730
DATE AS OF CHANGE:		20150730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		151015061

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d52781d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of July, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 30&nbsp;July 2015 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781tx_pg03a.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary&nbsp;Shares&nbsp;on&nbsp;issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">424 M</P> <P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ian Phillips MNZM</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interim Chairman</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Iain Ross</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting CEO</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steve Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non-Executive Director</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Bryce Carmine</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKET RELEASE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">30
July 2015</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><B>NEWLY APPOINTED ACTING CEO OUTLINES IMMEDIATE PLANS
FOR NOVOGEN</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><B>COMPANY CONFIRMS ITS COMMITMENT TO BRINGING
TECHNOLOGY PLATFORMS TO THE CLINIC</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><B>Sydney, July&nbsp;30,
2015</B> - US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today confirmed it is committed to progressing its ground-breaking technology platforms to Phase 1 clinical trials as soon as practicable and to ensure the
Company delivers the best value for shareholders.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">Acting Chief
Executive Officer, Iain Ross, said the Company currently had an extensive program of activities underway including the lead pre-clinical programs, discovery programs and academic partnerships and initiatives, and he was working with the newly
evolved Board and incumbent Scientific Management Team to review the Company&#146;s immediate priorities with the intent of providing a shareholder update by 1&nbsp;September 2015.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">&#147;We remain committed to exploiting and creating value from all
our technology platforms in order to build a sustainable, international, biotech company. Whilst we do not rule out securing third party collaborations and partnerships to further validate and fund our programs, I can confirm there are no M&amp;A
plans,&#148; Mr Ross said.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">&#147;Notwithstanding, it is clear
that we cannot realistically undertake and fully resource all our research and development programs in parallel all the way through to market approval and launch. These are new ground-breaking and first in class technologies and it is critical that
we understand which indications, stage of disease and combinations with other oncology agents will deliver the best outcome for patients and value for shareholders.&#148;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">&#147;Accordingly I have initiated a Company-wide review and I am working closely with the Board, Management and Company&#146;s scientific
advisers to review immediately the pre-clinical programs in detail, including the targeted indications, route of patient administration, product formulations, manufacturing scale-up and regulatory requirements,&#148; Mr Ross continued.</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Whilst not wanting to pre-empt the outcome of the review I anticipate we may have to re-prioritize some
of the programs as outlined in the PRODUCT UPDATE section below.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;One outcome from this process will be to focus our valuable resources; set
clear, realistic, scientific and commercial priorities in order that we can execute and manage the business effectively and report our on-going progress to our shareholders against the priorities we have established. We know already we are
under-resourced in some areas and therefore I have commenced the search for a world class CEO and authorized the immediate recruitment of additional staff including a full time CMO, project, and manufacturing management support. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We operate in a highly competitive market place and we will ensure as an organization we are fit for purpose.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In summary Novogen is in an excellent situation. The Company is in a solid financial position with a suite of promising drug candidates. Novogen has
world-class science, a scientific team of the highest quality, and some strong academic partnerships. I am delighted to be able to lead the Company through this period of transition and intend to keep shareholders updated,&#148; Mr Ross concluded.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRODUCT UPDATE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has two drug technology
platforms - the Superbenzopyran (SBP) and anti-tropomyosin (ATM) - around which the Company has established very strong patent positions. Our medicinal chemistry programs have identified two promising drug candidates (Cantrixil and Anisina), which
the Company is progressing down the translational development path in concert. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cantrixil </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantrixil is being developed by the Company&#146;s subsidiary company CanTx (a joint venture between Yale University and Novogen). Cantrixil has been designed
to be injected into the peritoneal cavity with the aim of treating both differentiated cancer cells and cancer initiating cells, the cells thought to be primarily responsible for cancer recurrence post chemotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Yale collaborators have demonstrated that Cantrixil modulates both the JNK and PKC pathways resulting in caspase-mediated cell death. Yale researchers
also demonstrated that Cantrixil was active in a stringent, clinically relevant rodent model of human ovarian cancer. Pending successful completion of our toxicology program, an initial first-in-human clinical study assessing the safety and
tolerability of Cantrixil in late-stage cancer patients is planned to commence in 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Company&#146;s pre-IND meeting with the US Food and Drug
Administration (FDA), the agency agreed with our strategy on manufacturing and toxicology evaluation. Subsequent to this meeting, the Company has been able to produce both the active drug substance and drug product that both meet Good Laboratory
Practice (GLP) standards. Critically the drug has shown an excellent stability profile, all manufacturing processes have proven robust and scalable. Novogen has commenced manufacture to Good Manufacturing Practice (GMP) standards enabling the
Company to meet product demand for clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has commenced its Cantrixil toxicology evaluation with the aim of gaining Investigational New
Drug (IND) status with the FDA. This evaluation will characterize the toxicology signals associated with the experimental drug, and correlate any toxicities with drug concentrations achieved in mammalian models. This information will enable
regulators, such as the FDA and clinical investigators to assess the drug&#146;s safety, ascribe a starting dose in humans and to establish monitoring of potential toxicities encountered in humans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results to date indicate that the drug is associated with gastrointestinal toxicity manifest as diarrhoea and some haematological toxicity manifest as
anaemia. Also, while not uncommon for oncology drugs, preliminary studies suggest that Cantrixil is associated with cardiovascular toxicity though this observation is being assessed further. The Company anticipates completing the Cantrixil
toxicology evaluation by the end of 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has assembled a Medical Study Committee for Cantrixil and commenced writing the Phase I clinical trial
protocol where the Company will assess the safety and tolerability of Cantrixil in late stage cancer patients. Novogen is also planning to conduct a second trial in women with late-stage ovarian cancer who have become unresponsive to standard of
care therapy once the Company has received IND status for Cantrixil from the FDA. The FDA recently granted Cantrixil Orphan drug status for ovarian cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Progress and timing of these clinical studies will depend upon the outcome of the toxicology program and therefore it is not possible at this stage to be
precise as to when clinical studies will commence however the Company continues to aim to start the trials in 2016. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anisina </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anisina is an anti-tropomyosin (ATM) small molecule targeting a protein component of the actin microfilaments, tropomyosin Tpm3.1 which is essential for tumor
cell survival. In vitro studies confirm that inhibition of Tpm3.1 function impacts the structural integrity of the cancer cells cytoskeleton causing the cancer cell to die. In addition to being an effective anti-cancer agent, these ATM compounds are
also novel in that when administered to animals and used in combination they can enhance the killing effect of one of the most widely used classes of chemotherapy drugs in cancer- the anti-microtubules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preclinical studies are underway to validate the effectiveness of Anisina in animal models of adult (prostate and melanoma) and pediatric (neuroblastoma)
cancers both on its own, and in combination with standard of care microtubule inhibitors. Importantly, a proof of concept study done in an animal cancer model as part of the Children&#146;s Oncology Drug Alliance (CODA) has confirmed that Anisina is
not only effective on its own in reducing neuroblastoma tumor growth but also enhances the sensitivity of cancer cells to microtubule targeting compounds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has successfully optimized the manufacturing process of the Anisina Active Pharmaceutical
Ingredient (&#147;API&#148;) using a process that is scalable and meets GLP standards. The process has proven robust and as a consequence manufacturing programs were completed 6 weeks ahead of schedule. The GMP manufacture of material for clinical
trials has been accelerated to commence in August. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has identified the drug product that the Company intends to use in the clinic. This has
enabled the Company to initiate its Anisina toxicology program with a view to filing an IND with the FDA. The Company has assembled a Medical Advisory Board for Anisina and, based on our pharmacology package, anticipates initially taking Anisina
through to the clinic as an IV delivered drug in combination with taxanes or vinca alkaloids targeting prostate, melanoma or neuroblastoma. Further studies are ongoing to identify the Anisina adult cancer indication. The FDA recently granted Anisina
Orphan drug status for neuroblastoma. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pending the outcome of our Anisina toxicology program and discussions with the FDA, the first-in-human studies
are predicted to start in 2016. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TRXE-009 (Trilexium) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TRXE-009 is the Company&#146;s second lead SBP drug candidate. Researchers have shown in animal models that Trilexium affects the viability of cancer cells by
increasing rates of cell death (via caspase-mediated apoptosis) and reducing proliferation. This was observed in cancer cells representative of Glioblastoma, melanoma and prostate cancer. The Company has also demonstrated tumor growth inhibition in
several other animal models (flank models of melanoma, prostate and GBM). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These findings combined with recently announced pre-clinical in-vitro studies
demonstrate that TRXE-009 is highly cytotoxic to chemo-resistant pediatric brain cancers including Diffuse Intrinsic Pontine Glioma (DIPG). Using a proprietary formulation, animal studies have confirmed that TRXE-009 inhibits the proliferation of
prostate, melanoma, and GBM tumors grown subcutaneously (under the skin). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A major hindrance to the use of chemotherapeutic agents for brain tumors is the
presence of the blood brain barrier, which blocks drug access to the brain tumor. To counter this, the Company has identified a micelle formulation that was able to deliver potentially therapeutic concentrations of TRXE-009 to the brain tissue of
rodents. This finding represents a step forward in the development of the drug with the next key step being to demonstrate that this micelle drug product inhibits the growth of human brain cancer cells growing in the brain of rodents (orthotopic
model of human brain cancer). Another key goal will be to demonstrate anti-tumor efficacy of the micelle drug product in rodent models of prostate cancer and melanoma. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Once Novogen has optimized the TRXE-009 formulation and confirmed activity in the above key studies, the
Company will commence the requisite toxicology program required prior to the conduct of a first-in-human trial in 2016/2017. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jacob&#146;s Hope
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jacob&#146;s Hope is the name the Company has given to the degenerative disease and regenerative medicine program that is highly experimental and
investigational. It is named after a very brave young man called Jacob who has a disease known as Duchenne muscular dystrophy (DMD). Jacob and thousands of children like him around the world, is the reason we are running this program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jacob Hope consists of three exploratory programs: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Regenerative Medicine Program, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Facioscapulohumeral muscular dystrophy (FSHD) program</B> and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Lysosomal Storage Disorder (LSD) Program<B>.</B> </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regenerative Medicine </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Studies in the test tube have demonstrated that SBP analogues are able to promote the differentiation of neural progenitors into functional neural cells. The
Company has commenced a medicinal chemistry program aimed at refining the SBP chemical scaffolds with the intention of identifying lead compounds that can be appraised in an appropriate model of brain injury such as stroke and traumatic brain
injury. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FSHD </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s initial evaluation
of a panel of SBP analogues in an in vitro model of FSHD using diseased embryonic stem cells have demonstrated that discrete analogues may have a positive effect on the phenotypic appearance of myotubes when compared with the formation of myotubes
with no treatment. This is an intriguing finding as the screen may provide a tool by which a medicinal chemistry program could identify potential lead analogues to progress into in-vivo translational models of FSHD. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LSD </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contracts are in place with a world expert in LSD,
where a panel of SBP analogues will be assessed in human fibroblasts isolated from patients with LSD. These fibroblasts are unable to prevent the accumulation of intracellular heparan sulfate, which leads to the death of the cell. The aim of this
screening program is to identify a subset of analogues that inhibit this accumulation and thus rescue cell function. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the data achieved to date in the Regenerative Medicine and FSHD programs, the Company intends to pursue
patent protection around the discrete SBP pharmacophores that are attributable to either potentiating neurogenesis in the Regenerative Medicine Program, or normalizing the myotube phenotype in the FSHD program. The Company will also endeavor to
protect any SBP pharmacophore that is active in the LSD setting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This patent protection strategy will increase the intrinsic value of each program and
establish a priority date from an intellectual property perspective thereby enabling the Company to re-visit each program that has promise when funds and time permits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Children&#146;s Oncology Drug Alliance</B> (<B>CODA) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CODA&#146;s mission is to accelerate development of innovative new therapeutic approaches to the treatment of childhood cancers and to take account of the fact
that childhood cancers are different from adult cancers and the lifelong consequences of side-effects from cytotoxic treatment can be far more devastating in a child than in an adult. CODA unites the research and resources of five organizations in
Australia and the US. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Australian members are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The charity, <B><U>The Kids&#146; Cancer Project</U></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The originator of the anti-tropomyosin technology, the <B>University of New South Wales</B> and its commercial arm, <B><U>New South Innovations</U></B> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Biotechnology company, <B><U>Novogen Limited</U></B> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The US member is the: <B><U>Nationwide Children&#146;s
Hospital</U></B>, Columbus, Ohio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is providing access to both its anti-tropomyosin and super-benzopyran drug technologies. Anisina is being
evaluated for its ability to complement the action of standard chemotherapies in childhood cancers. TRXE-009 is being evaluated for its ability to treat brain cancers in children. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information on CODA is available at <U>www.childrensoncologydrugalliance.org</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781footer.jpg" ALT="LOGO">
 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781header.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a public, Australian-US drug development company whose shares trade on both The Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen
group includes US-based, CanTx Inc., a joint venture company with Yale University. Novogen has two drug technology platforms [the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)] yielding drug candidates that are first-in-class with potential
application across a range of oncology and degenerative diseases. Given the encouraging data from in vitro and in vivo pre-clinical Proof-of-Concept studies in the field of Oncology, our immediate focus is to advance our lead Oncology drug
candidates pending successful completion of their respective toxicology programs. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the potential clinical
indications being pursued, with the ultimate objective of employing both technologies as a unified approach to therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please
visit <U>www.novogen.com </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kym
Robins </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketing and Communications Manager </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Group
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">E: <U>Kym.Robins@novogen.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;2 9472 4109
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward Looking Statement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press
release contains &#147;forward-looking statements&#148; within the meaning of section 27A of the Securities Act of 1933 and section&nbsp;21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by
use of such words as &#147;expects,&#148; &#147;appear,&#148; &#147;intends,&#148; &#147;hopes,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148; &#147;should,&#148; &#147;would,&#148; &#147;may,&#148; &#147;target,&#148;
&#147;evidences&#148; and &#147;estimates,&#148; and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company&#146;s
drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company&#146;s drug development program, including, but not limited to, Cantrixil, Anisina, Trilexium, and any other statements
that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production
and marketing of the Company&#146;s drug components, including, but not limited to, Cantrixil, Anisina, Trilexium, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate
therapeutic efficacy of the Company&#146;s drug compounds, including, but not limited to, Cantrixil, Anisina, Trilexium, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company&#146;s intellectual
property or trade secrets, including, but not limited to, the intellectual property relating to Cantrixil, Anisina, Trilexium, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission
including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management&#146;s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties
mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g52781footer.jpg" ALT="LOGO">
 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g52781footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g52781footer.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X00,:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C4M8S`R,2`W.2XQ-30Y,3$L(#(P,3,O,3`O,CDM
M,3$Z-#<Z,38@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z1#5$.30Y,$$R0C@T,3%%-3DR-#=%-T)$1CDV
M0S,Y,S,B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z1#5$.30Y,#DR0C@T
M,3%%-3DR-#=%-T)$1CDV0S,Y,S,B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HX.&(R.&$P-RTX,#=D+31D,#$M.3(T-2TR
M.31F.39D-V4Y,3DB('-T4F5F.F1O8W5M96YT240](G5U:60Z86$Y9CDR934M
M8S@W9"TT-&8Q+6%F93DM,&%F.3DT8C%F9C<R(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YR<C4P-3DU-#PO<F1F.FQI/B`\+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B`\<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9"`M(#$M,RYD;V-X
M/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D8SIT:71L93X@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0]
M(G(B/S[_[0!(4&AO=&]S:&]P(#,N,``X0DE-!`0```````\<`5H``QLE1QP"
M```"``(`.$))300E```````0_.$?B<BWR7@O-&(T!UAWZ__N``Y!9&]B90!D
MP`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`@$!`@("`0("
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`__``!$(`#H"Q@,!$0`"$0$#$0'_Q`#*``$``@(#`0$!````````````
M!08$!P(#"`$)"@$!``(#`0$!``````````````0%`0,&`@<($``!`P,`!0@#
M"@@-`P4````!``(#$00%(3%1$@9!87&1,A,S!X$4-:&Q(D)28I(T-@C!<H*R
M(T-C<_"BPE.#LR1$=+05=3>$%G;19$4F1A$``@$#``0+!`<$"@,!``````$"
M$0,$(3$R!4%187&!D:&Q$C,&P2)R--%"8K(3-0?A@B-S\%*2HL)#@Q1$%?%T
M)3;_V@`,`P$``A$#$0`_`/[B:G:>LH!4[3UE`*G:>LH!4[3UE`*G:>LH!4[3
MUE`*G:>LH!4[3UE`*G:>LH!4[3UE`*G:>LH!4[3UE`*G:>LH!4[3UE`"XM!<
MYVZT:W$T:.DDT"#4JO44_B#C'AC%V=W'>YJS[P0NK!;R&]FUC]7:B8M-=M%M
MA8O3TQBZ$&_O/`Q_,NQ\7$M+ZE4TAD/.#$P[S<9B[V^<"0V2Y?'90FFIVZWU
MB:AYP"I$<&X]MI+K*B]ZEQXZ,>W.3XW[J]K*-D?-7BB\WFVCK/%QFH`M;<2S
M`$Z/T]R93O`:*AK5)CAV8Z75OE_855[U!O"[HMN%N/(JOK=2C7^7RN4?OY'(
MWEZZM1ZS/)(T$_)83W;?0`I$;<(;*2*J]D7\AUOSE-\K;(Y>C2$`0!`$`0!`
M$!D6UY=V<@FM+F>VE&J2":2%_1O1N:ZBQ*,9*DDFCW"Y<MR\=N3C+C3H^PNN
M/\RN+;"C77\>0C'ZO(P,G-/DB=G<W`'Y14>6)9EP4YBSL[\WE95'-37VE7MT
M/M+SC_..`[K<KA98S0`S8^X9(VM-+NXN1&X`GD[PJ/+!?U)+I+:SZECJR+3Y
MXNO8_I+UCN/^$LEN"/+1VLK]T"'(,?9O#C\7?D'<$UV/(4>6->AI:JN0MK.^
M=VW]"N*,N*7N]^CM+=%)',P20R1S1D5$D,C)6$;0^,N:>M:-6AZRRC*,U6#3
M7(ZG-#(0!`$`0!`$!:L(?[))^^?^;$@)>IVGK*`5.T]90"IVGK*`5.T]90"I
MVGK*`5.T]90"IVGK*`5.T]90"IVGK*`5.T]90"IVGK*`5.T]90&)=W+[=K-T
M`N?6A<31H;2N@$5)0$2^ZN'ZY7`;&_`'\6B`Z*G:=.O3K0"IVGK*`5.T]90"
MIVGK*`5.T]90"IVGK*`\?\5M<_BGB`-:7N.8O]#6ESC^G=R`$E7=E_P8U_JH
M^9[PT[RO+2_XDN\PX,'E+@`LM'L:[2'S;L(IMH^CO<7IWH+A/-O#OW=F#2XV
MZ>VO8<;_`,J\%GQ_]BL,5?$BA+K)LEP*FIW;ND,S/05B&=<LO^$VND\7O3&'
MG?/6[4OW:OHEH:*;D?N]>6V-M;S)6>-NWS6T,EQZO?W]S>6+FQ_"=&VW<YI9
M4=FKG`4U*1'>N9<:A*2HWP))]959/H+T_CVIY-JW)RBJTE)RCHY/_)!6>/L,
M='W-A96ME%_-VL$<##3:(VMWCTK=*<I.LFVR'9L6,>/@L0C"'%%)=QF+R;0@
M"`(`@"`(`@(K)8+"Y=N[E,78WPINAUQ;L?(T:.S+02MU<A"V1N7(;$FB+D8.
M'EJF3:A/G57UZ^TU_DO)[A2\#W63LAB97;Q;ZO<>LV[7'5_9[L2.W!L#VJ5#
M/OQVJ275VHHLGTGNR]5V7<M2?$ZKJE7O1K_)>2N=@WG8O*8_(M%2V.X$MA.X
M<@J?6("[I>T*3#>,'MQ:?)I*'(]'YUO3C7(7%Q.L7[5VFOLGP9Q7AP77^#OX
MX@2._AC];M]`J3WUHZ9@%.4T4N&39N;$E7J[RBR=T[SQ//LW%'C2\2ZXU*Q6
MA(-01K!J".D'2%NTE=7@X030$Z=`J@JSV[Y=?=4P>;P&#XCXHXGR<[<UC++*
MLQ6$@@L8X(;Z&.YBAFR%TV[FED;%(`_<BC&]6AII7.96_+MN[.S9@EX9-5;K
MJ=-6@^R>G_TRP\W!L;PWEDW'^-;C/P6THI*232<I>)MT:K1(]'<.^1GE3PP8
MY+#@['7=U&=YM]FC+FKS>T?"#L@^6!A%-&[&VBJ;N\LZ]HG<:CQ+0NP^A;O]
M%>F-VT=C$MRN+ZURMR7]ZJ70D;6CBCB8V.*-D4;`&LCC:UC&-&IK6-`:UHV`
M*%5MU>LZ>,(12C%)16I+0D63#>!/^]9^85IN:^@EX^IDRUSFG>:XM(Y02#UA
M:R09T>2O(_UI>-5)`'_QC\(=:`EK+)/N9.Z>S==0D.:XTT::%IJ=0VH"4J=I
MZR@%3M/64!\0!`$`0!`$`0!`$`0!`$`_AIT#TGD0&K\YYJ83&3S6EA;S9>XA
M>Z-\L3V06+9&U!#;AP>^<-<*$L9385+MX=R:\4GX4^LH<KU!BV).W9B[LTZ5
MK2->?37H1KK(^:_$]WO-LVV.*83H-O!ZS.!3^>NS(VO.&!2H8=I;56_Z<127
MO4.\+GE^"VN15?6Z]Q1[_-YG*FN1RE_>BM=R>YD=$#I&B$.$+=!Y&J3&$(;,
M4N@JKV3DY#K?N3GSMTZM1`WM!:7%!^J=H`YP3H"]D>E-125@R$`0!`$`0!`$
M`0!`$`0!`$`0&79Y"_Q[^\L+VZLG_*M9Y8"=1T]VYN\-&HU"Q*,9;23-EN[=
MM.MJ4H/D;7<7;'>9W%EC1LMW#DHP`-S(0,>^@V3P]S-7I)4>6)9EJ5.8M+&_
M-XV7[TE./VE[51E\Q?G!8S.9'F,7-9U-'7-E*+J%NH;SH)!'.`.7=+SS*-/!
MDM-MUYRWQ_4EJ34<FVX\L75=*>GJJ;=M;JWO;:&\M)F7%M<1B6":,[S)(W:G
M`\G.-8.A0FG%^&6AHZ.W<A=@KEIJ5MK0T=ZP>P@"`("UX4$6;R=&],_=YQ2,
M5'-5I0$J@"`(`@"`(`@"`(`@"`("-R?9@_+]\(")0!`$`0'%SFM[1I_#F0'4
M9Q\45YSH0'69GG51O1K]U`:>R44;,IDGLCC8^2^N'R/:QK7/>Z0DN>X`%SB>
M4J;%MP2>JAS%Z,5EW*))N3X.4PUDP$!$YWV+E?\`;[K^K6RUYD?B(N=\E=_E
MON9Y]5L<($`0!`$`0!`$`0!`$`0'T$C42.@H"%R7#F`S%?\`4\/CKUQ%.\FM
M8^_YJ7#`R<4YG+9"[<M[$FNDAY&[\'+^9LVYOC<57K6GM-?93R;X6O-YUA+D
M,0]PT"&87=N/Z&[#Y*<FB0*5#/OQVJ275W%%E>DMVW:RL.Y:ER/Q+JEI[3]`
MN"<0_&\%\)X]LS9Q9<.8>U$I;W1D[BP@CW]PN>&[V[6E31<QD2\>3<GPN;?6
MZGW3<^*\7=6+93\7@Q[<:ZJTBE7L+"]KF'=>-T\E>7HVK26.IT9Q0%BPW@3_
M`+UOYA6JYM=!)L:F2ZUD@("2Q7UH?BN_-*`LR`(`@"`(`@"`(`@"`(`@/H!<
M:-!)V`$GJ"!)O41%SG\!97++*]SV$L[QYW66EWE\?;7+G?)$$URR7>TZJ+VK
M=R2\48R:YF1KF;A69JU=O68W'P.<4^INIG77PK&ZD:0Z-]G<N9(PAS'CN)*.
M8]M6N'."O,=I+AJC;<=;,I+5X):>AGB1NH>CW@K\^60V3DAZ"`^(",FQ-K*2
MYH=$XU)W#\&I^::@>BBR-)&RX28:8I(WC8ZK'<GXS?=0:3`EL;J'2Z&2G*0W
M>'6VH6!4Q.;E"`(`@"`(`@"`(`@"`(`@"`(`@/4WEK]CL;S37X',/6WZ.A5&
M7Y\NCN.]W#^5PYY?>9>U&+@[X[6XF\.&1XVAAW=O:(#4!(QX6Z?3O'1Q`BNE
MQ>X>A@(]U`2,6&MF4,CWS'8?@,U\H;5QKTH"5:UK&AK&AK6BC6@4``Y``@.2
M`(`@"`(`@"`(`@"`(`@(W)]F#\OWP@(E`$`0!`84G;=TH#@@"`U-E/:5_P#X
MR?\`/*F1V5S',W_FI_$^\P%Z/(0$3G?8N5_V^Z_JULM>9'XB+G?)7?Y;[F>?
M5;'"!`$`0!`$`0!`$`0!`$`0!`$!?L/YD<2XB"WL^\M;^RM6-BB@O(/ALA8`
MUD3+F!T4H:QH`%=Z@"C3Q+4Y.6E29=XGJ#>.)!6DXSM1224EI27!54?74F\S
M]X#A_A_&1W_$V&R5M`Z\MK4S8HQ9'NY)VRG?,$S[281M[O3NE[N8K7#==V]/
MP69)RI73H)F5ZXP<&Q&_O*S<C!S4:PI+2ZM:&XO@Y2<X>\Z_*SB<1MQO&>(A
MN)>S8Y>5V%O:UINF')MMFN<3JW7.JM5W=^;9V[<J<:]Y=A/W?ZR],[S26/EV
MHW7]6;_#EU3\/8V;QP#X[FVEDMI&7$;Y&%DEN]LS'@L-"U\1<UP/,56W4U*C
MT.AUN+.$X.<&I1?"FFNM%GCQUY**B%S6TKO248.IU">I:R49T>'.@RS`;6QM
MK_&<1[R`DK>RM[8[T;7%]*;[G$FAYA1ON(#+0!`$`0!`$`0!`$`0&E_,WSTX
M1\KKV#$Y6TS&5S5S91Y"/'8R"%C&6DTDL4,MQ?W<L5O%WDD#J-:)'4%2!H4[
M%W?>RXN<'%03I5_0CEM_>KMV^G[JQLB-VYE2@I*,$M3JDW)NBTIZ-+/,?$'W
MP.++LOCX8X8PF#B(`9<Y.6XS=\#RNW&G'V3:CD+'TVJUM;FLQTW92D^30O:S
M@LW]2]XW&XX%BU:CQS;G+_#'L9HSB+SB\SN*M]N7XTS7J[Q0V6-N!AK&E2:>
MK8IMHQ^NE7[QIRJ?:PL6SIA"->-Z7VG)9OJ??^\*K)RKOX;^K%^"/5#P]IK1
MX$CG22?I)'G>>^3X;WN.DN>]U7.<3RDU4K5J*)KQ.LM+99L1QUQIPM!-_P!O
M<4YW$L9!-2WM<C<"S([MY+76,CY+-[#72#&05IN8]B[YD(M\=-/7K)^-O?>F
M[X/_`&61>MQH]"D_#_9;<>PUW@_O,>86.$3,I#A.((6T#S<V;L?=N;O:3ZSC
MGQ0[]-%3"Y2KF[,>6QXHOGKWD'&]:[VQWX;ZMWH+C7A?7&B[&;OX3^\IPOG\
MA88G*87+8.]R-U;V-O*Q\&4Q[KJZE9!;L?+%ZO=0LDED`WC"0VNDTTJ#=W;=
MMQ<X24HI5XG_`$Z3I]W^M<',O0Q[UJY:N3DHK5*-6Z+2J/IH>D#H)!U@T/2%
M7'9U1\6!4^H`@"`Z9+>"7Q(HWUY2T5^D/A(*$?)A[5]=PR1'DW2'-ZGU-/2@
MYB.EPL[=,4D<@V&K'4]-6U]*R"/EL[F'Q(7@?*`WF_2;4+`J8R`(`@"`(`@"
M`(`@.Z.VGF\.&1X.HAAW?I:``@)&+#73],CHXASG?=U-J/=0'K7RPPMNW@W&
M.EDDD/?7]6BC&?7)1R5=J&U5&7HOR7-W'>[A_+(?%+[S-F16=K#3NX(P1J<Y
MN^_Z3]XJ,7!DH`@"`(`@"`(`@"`(`@"`(`@"`(#HG@9<-`>7#=KND<E=>@Z"
M#1`1[\=(*EDC7;`06D^^-"`Q7VT[.U$_I`WAUMJ@.A`$!A2=MW2@."`(#4V4
M]I7_`/C)_P`\J9'97,<S?^:G\3[R%N;^QL@3=WEM;`:^^F8QW0&$[Y/,!5>X
MQE+939'N9%BRJW9QCSLK-WQS@[?1`ZYOGZJ00F-FK^=G[L4Z`5OCBW9:Z)%=
M<WWAPV/%-\BHNME/R_&UWD;>:SMK2*T@G88I7/>Z>=T;C\-H-&1LWFBFHGG4
MFWC1@U)NK14Y>^+V1;E9MQ4;<M#X73N12%)*<(`@"`(`@"`(`@"`(`@"`(`@
M"`U1YS?8UG^]8_\`J[M3MW_,?NLYGU;^51_GQ[I'E@@'00"-ATJZ/F)^HOW!
MB?\`L;S`;4[K>,,<&@DD-'^@QFC031HKR!<CZC\^W\#^\?H#]'&_^IS5P+)A
M3D]S@XCWBN=/L(0!`$`0!`$`0!`$`0!`$!^<'WM_^3[#_P`/Q'^=RRZ7<WRC
M_F/V'PW]1_\`]!'_`-:'?,\NJV.!"`^M:Y[@QC7/>=3&-+WGH:T%Q0)-NBTL
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M98(7C8Z)A_DU6%*2TIL2M6IJDXQ:YB-FP6/EJ6L?`=L3SNU_$?OM6V-^:UZ2
M+<W=C3V4X\S]CJ1<O#<HTP7,;Q\F5KHW=&\W?:?<6Q9$7K5")/==Q>7)/GT=
MU2)FQ=_!4OMI'-%?A1TE::<OP"2!T@+;&Y"6ID.YBY%O:@VN-:>XP""#0@@C
M6"""/05[(_#3A"`(`@.B6V@F\2)CCM+0'?2%"LBB(^7#6K],;I(CS$/;U.T^
MZL`CI<+<-KW3V2C8:L<?0:M]U9!'RVES#XD,C1MW=YOTFU"P#'H=AZD%3NCM
MYY32.&1Y^:QQ'72@051(18>Z>`7[D0/RG;Q'2UM??0$A'A8&^+))(=C:,'\H
M^ZLC22$=E:PT+((P1\8C>=UNJABAE+!D(#U+Y:?8W&_OK_\`SLRJ,SYA]'<=
M[N'\LA\4OO,OBC%P$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$!UOBB?VXV.Z0*
M]>M`8SL?`_L[T9)Y#O#3S.T^Z@(*>T>V5X:YK@'$::M.@[-(0'2+:0Z]T>FO
MO(#N;:M^,XGH%!^%`>+>-\WE_P#NGB2S&0N8[6#,7]O%#$_N6MB9.]@:3$&/
M?\$:=XE7V/9M_A1E32XH^5;VS,J6\+]K\22MJ[))+1H3?$40DN<7.)<XZW.)
M+CTDU)4I*BHM13\-7K/B`(`@"`(`@"`(`@"`(`@"`(`@"`(`@-4><WV-9_O6
M/_J[M3MW_,?NLYGU;^51_GQ[I'EE71\Q/U#^X-]A_,+_`,QQWNX&-<CZC\^W
M\'^(_0'Z.+_Y.<^#_<P^X>\ESI]A"`(`@"`(`@"`(`@"`(`@/._G#Y$8GS0R
ML'$`XENL%F;;&18QK/4HLECKF&WEGE@,L0EMKB"1K[AP<YKR"*?!J%8X>\)8
MD';\*E!NO$SB_4OHVQZAR5FJ_*SDQMJ.RI1:3;555-/3P/H/-$_W5.,[65Y=
ME\1D+5I.X[%]Z+N1NWU?(^J,C=S![U9_]Q8EJ4D^75V5.(E^F^]K;;=VU.VO
MZE?$^B7A7:S$/E#88`C_`%C#Y:20&F_DVSPP$[`(&10'2/E.7I9LKJ]R2IR&
M%Z6QL/YJW=<EPSJEV45.LG;2PL+%@;965K:,I0>KP11$@:-+V-#W>DE:W*4G
M5MLL+6-C652Q"$4N))$C%;7-YWD=I;W%W+W<E66\,D[^R14MB:\@5Y2O#:CK
MHD2(PG=K&TG*5-25>XKEAP#Q1>AKC8"R8[3OW\S+<TV]R.\GTC:P+T[]J*TN
MK(]K=6==2]SPK[3IV:7V%XP_EEZI<VMYD,KWC[:>*X;;V4!;&Y\+VR,:^><[
M^Z7-TT8#3E6B>7XDXQ6OC+3'W'^'.-R]<JXM.B7$ZZW]!M?:=JAG0!`$`0!`
M=4L$$XI-#%*/GL:X^@D5"RI2CJ9XG;MW%2<4URHBYL#82#]&V2W=4Z8WDMZ-
MV3>_`MJOS6O20Y[NQI;-8OD?L9%3<.3MTP7$<HV2-,3NL;[5M61%ZTT1)[LN
MK3;DI<^A^U$5-C+^#MVLI`^-&!*WKC+J+:IP>IHB3Q<FWM0=.-:5V&"=!(.@
MC6#H(Z1K"]$>O!PA`$`0''=;6NZ*[:"J`Y(`@"`(`@"`]2^6GV-QO[Z__P`[
M,JC,^8?1W'>[A_+(?%+[S+XHQ<!`$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$!
M]&L=(]]`0<_C2?CN]]`=2`(#4'&7E#BN);VXRV/O7X;*71,ET#%ZS87<Y&F:
M2'?9+;S2'M.82':]VNE3;&;.U%0DJP76<UO/TUCYUV638F[61+2]%8R?'36G
MQTZC3F3\FN-L?O/MK>RS$302'8Z[8)G`;+:\%M(7'8W>4^&?CRUMQ?*OH.8R
M/3&]K%7",+L?LO3U2HS760Q&5Q+RS*8R_P`<X&G]MM)[=I.QKY6-8[1L)4F%
MR%Q5@TT4E['R,9TR+<[;^TFN\CM>K2O9I"`(`@"`(`@"`(`@"`(`@!(&LTZ4
M!*V6#S&1+?4L9>3M=2D@A<R&AII,TNY$&Z==5XE=MPVFD2;.'E7_`"K<VN.E
M%UNB+7:^7&=G&]<36-E\U\C[A_-40-+!](J/+-MK93?86-O<.;/3<<(=-7V:
M.T^W7EQG(16WN+"]/(QDDD$A.QHF8&$_E!(YMIZTT9N;AS(^5*$WQ5:?;])K
M3CSR<\R^,\)'A.'^%;RYOO\`5;.X+KF>SQ]DV")EPV28WU[<06Q8TR#LN<XU
MT!3<3/Q+%W\2Y->'POC;ZCG=^^E]_P"],18F'C3=U78O2XQC1*57XI-+J9U\
M*?<.XWO9(9>-.+^'^';4FLUIA([GB#*!M`=ULLK,=C8Y*Z"=^4#85LO>HL>*
MI8A*3Y="]K(.[?T@WM=<9[TR;-BWPJ"=R?;X8KGJ^8_0;RT\LN%/*?AJ/A?A
M*UFBM3,;S(7UY*)\CE\B^-D4E_?SAK&&1S(PUC&-;'$P!K0`N;R\N]FW?Q;[
MT\"6I+B1]HW#N#=OIS`6[]VQ:MU\4I-UE.7#*3X^)))):$J&P%%+H(`@"`(`
M@"`(`@.#Y&1BKW!M=6T]`&DH#%=?,'88YW20T?A*`QW7DSJTW6#F%3UNJ@,=
MSWO[3G.Z22.K4@."`(#XX![2QX#V'6QX#F'I:X%I0PTFO"]ED#-PKPS<3=_/
M@,3)-6I>;.)M3M<U@:QWI!6U7KRT*4J$26[L"<O'*S;<OA1+-M[>TMI8K2W@
MM8Q#*!';0QP,IW;OBQ-8%XJW)-Z74D*W;M6W&W%1C1Z$DNXTT[7Z![RF'.,X
MH8"`(`@"`(`@"`(`L`Z9;:WG%)H(I.=\;2[3\ZF\.M>U.2U,USM6KFW&+YT1
M<V`L)*F,2P./R'[S0?Q9`[1Z0MBR)K71D2>[<>6F%8ODU=3(J;ARX;I@GBF'
MR7@Q._EMKZ0ML<B+VE1D.>[+J\N49<^C]A"W-I<6C]RXB=&3V2:%KOQ7@EKN
MM;HRC+9=2%=LW;+I=33[.LQUDU!`$`0'QQ#6E[B&,&M[B&L'2YQ#0G)PAM+2
M]"#2'-#V$/8=3V$.:>AS26E9"::JM*/JP#U+Y9_8W&_OK_\`SLRJ,SYA]'<=
M[N'\LA\4OO,OBC%P$`0!`$`0!`$`0!`$`0!`$`0!`$`0!`$!PEDB@C=-/+%!
M"T$NFGD9#$T`5)=)(YK&@#:42;=%I9B4HP7BFTH\;T(U[F/-KR\P3W1W?$UE
M<W##IM<4V7*S;P%=VMDR6`./.\:5*MX65<V8-+C>CO*7)]1[EQ'X;E^,IK@A
M6;_NU7:5:Z\T+.X8VXQF,NGLN6-GA?D'-M#N2MWF;]O'WT@-#I&\%E8DDZ2:
MKR&M[^M3@KEBW)QDJKQ>[KY-+*Q=<=\17!/=SP6;=-&VULS>`/[2?OGU`6Q8
M]M:U4@W-[YL]345R+VNIA1\8<2QNWAEIWZ:[LL=O(P]+714HO7X-JE*&I;SS
MDZ_B-]"^@L%GYC9.*C;ZSM;MN@%\1?:R\YT=[$XD?-"UO&@]EM$RUON_'1=A
M&2Y-#]J+79\?X&XW1<>M6#SK$T/?1`_O8"\TZ6A:7CW%JHRQM;YQ)[?B@^55
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M;>6L]MJ-#0RL:UPKR@D*5&<9JL6F4MVQ?QY>&_"<)?:37>82R:@@"`(`@"`S
M[#&9')O='C[*XNW-IO\`<LJR.NKO)#2-E><A>9W(6U6;21NLX]_)EX;$)3:X
MM72]2+A9>7.=N*.NY+/'L.L/E-S,!R`1P`LJ>=X4:6;:6S5LM+6XLRYYCA;7
M*ZOJ7TEMLO+;$0@&^N[R^?K+6%EI%T;L?>2G3\\*-+-N/9219VMP8L?.E.;_
M`+*]K[2\XSA"QM@TX[!0-+:?IWP!SR:=HSW6\\GH*CSOW);<F7./NJS;\BS%
M<K6GKD6R'AZZ>`9YHH0/BMWIG4V"@:P=:T.:6HLXX-Q^8TEU_L).'`64=.]=
M+.=?PG=VWZ,=#3TE>7-O42(85F.U61*Q6MM`*0V\,?.V-N]](@N]U>6V]9)C
M;MPV8I=!E,U^C_T6#V9;+F>.FY*\`<E26_1-0@,QF4G;VVLDZ!N'W*CW$!FL
MR=N[MA\9IRC?%>ENFGH0&;'-%*"8WM?370Z1TC6$!V(`@"`(`@"`^C6.GEU>
ME`1%WXSNUV6Z]7)J^;^%`8J`(`@"`(`@"`XO[$G9\.3M=GL.[7S=JRM9AZGS
M&E']MVK6=79UGL_-V<RF\!S+UG!#`0!`$`0!`$`0!`$`0!`$!#<0>S3V/&B[
M>O6?!^?MYJK=8VROWE\MP;2Y^@HZF%$$`0'3<>!-]8\-WU7ZSJ_N_P"UV<Z]
M+6M72>)[+VM7!KZ.4\>>9_UE_P#R/XA^U'LG_IN;Y/,KK$_TOW=9\_WWMOYS
M_4V1Y7_6F?\`(W;_`/S'LKLGZU_#4L9>I^5TZS&Y/,7S>M>5L])["@\&+ZSX
M;?K7UC5^O_;?*YU3/HZ#Z##4MK5P^WE/6?EW]CL/X/8N/`U?6I_%_P#<?+^<
MJ7*^8EKZ3Z%N3\NMZN'5S\/+^TNJCEL$`0!`$`0!`$`0!`$`0!`$`0!`$`0!
M`8>0^I7/M#PW>R?:7_2?M=B]1VN#IU&J_P"3+:U?5VN@\%>:GM)W_(WBN^W7
MU34/J?S?P+H\34O*U?4/D'J#S7\_K_Y&KH]G(63R[[$/V"U?W7VUV1J_:;5$
MS=;\[IV2Z]/[*^0UK9\PW3DOJ;/97A__`"?XKO#YU7V]?#T'896Q_E:OKFLI
M_%?X&O\`NW@?T?,I:U</3K.;N;;V=?!JZ#J63R$`0!GB-UZV^'XNOXG/LYT,
M+:7LU]!N_A/PF?:CLCVK]2[(\/FV>A0+FOZG0=7NW9_Y'#M[/07=:"V"`P<Q
M[.G]F>$_V[[+U?K_`)B]0VN'HUFG*\A^7K_S-CI/%7&WM$_8SMO^Q_@_T_X.
M=7^/J_S/WCY9O;SO^-K?D:NDI2WE6$`0!`$,F\O+;[/R=CVC<=GM>'#XG\GF
M55F>;T'7[@_+W\;U>WV%_P"7EY.C6HI=(MF(Y/9?]']:U^^M,NDM<74O+Z-9
J9#KY?3K7@G'Q`$`0'-FOT?A"`[4`0!`26+^LG7X,GX-:`GD`0!`$!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g52781header.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g52781header.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X00,:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C4M8S`R,2`W.2XQ-30Y,3$L(#(P,3,O,3`O,CDM
M,3$Z-#<Z,38@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z13(R,4-$,C(R0C@T,3%%-3@Y13%$-3%%1#E$
M,$(V,C(B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z13(R,4-$,C$R0C@T
M,3%%-3@Y13%$-3%%1#E$,$(V,C(B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HX.&(R.&$P-RTX,#=D+31D,#$M.3(T-2TR
M.31F.39D-V4Y,3DB('-T4F5F.F1O8W5M96YT240](G5U:60Z86$Y9CDR934M
M8S@W9"TT-&8Q+6%F93DM,&%F.3DT8C%F9C<R(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YR<C4P-3DU-#PO<F1F.FQI/B`\+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B`\<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9"`M(#$M,RYD;V-X
M/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D8SIT:71L93X@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0]
M(G(B/S[_[0!(4&AO=&]S:&]P(#,N,``X0DE-!`0```````\<`5H``QLE1QP"
M```"``(`.$))300E```````0_.$?B<BWR7@O-&(T!UAWZ__N``Y!9&]B90!D
MP`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`@$!`@("`0("
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`__``!$(`#X"Q@,!$0`"$0$#$0'_Q`#)``$``@(#`0$!````````````
M!08$!P$#"`()"@$!``(#`0$!``````````````0%`0,&`@<($``!`P,!!00$
M!PP)`P4!```!``(#$00%(3%1$A,&09$4!V%Q@2*AL3)"<Q4(4G*2HK(C,T-C
M-+06P=%B@E,D=#4V\,)U@[-%)G8W$0`"`0,!`P@&!0L"!`<``````0(1`P0A
M,1(%05%A<9&A,@:!L<$B$Q31X4(S-/!28G*RPB-S%34'DJ*"0U.SHR1$5'06
M-O_:``P#`0`"$0,1`#\`_N)J=Y[R@%3O/>4`J=Y[R@%3O/>4`J=Y[R@%3O/>
M4`J=Y[R@%3O/>4`J=Y[R@%3O/>4`J=Y[R@%3O/>4`J=Y[R@%3O/>4`+N%I<Y
MW"T;7.=PM'K<2`$#:2J]$4[/]:]+XNTNF7F:M'2"(U@M7NO9MHTX+42AI]9"
MW0L7IZQBZ=A`O\4X?CZ7+L=[F6K[JFD,AYP8J'B;C<5>7K@2&R74D=E$:=O`
MT7$U#Z0TK?#!F_&TEVE3>\RV(Z8]N4G^DU%>UE&R'FKU1=ES;5]GC(R"`+6W
M$DPJ?\>Y=,>(#M#6J3'#LQU=6^GZBJO<?XA=T@X6X_HK7M=2CW^7RN4?QY'(
MWEZZM1XF>21H.OR6./+9M[`%(C;A#PI(JKV1?R'O7YRF^ED<O1I"`(`@"`(`
M@"`R+:\N[.436ES/;2MV20321/']Z-S746'&,E2231[A<N6I;]N3C/G3HRZ6
M'F5U;84:;^._C'ZO(P,N#2E*<]G*N*?WBH\L2Q+DIU%G9XWQ*RJ.>^OTE7OT
M?>7FP\XX31N4PDC-`#-C[EKQ6FIY%R&$:_M"H\L%_8EVEM9\RK9D6GUQ?L?T
MEYQ_F#TED>!K,JRTE=0<K(1OM'!Q^;S'@VYUTT?11Y8M^.N[5=!:V>,\.O:*
MXHRYI>[W[.\M\4T-PP26\L4\9%0^"1DS"-_%&YS:+0ZK1EG&49JL&I+H=?4=
MB&0@"`(`@"`("V84_P"2=]-)\42`E:G>>\H!4[SWE`*G>>\H!4[SWE`*G>>\
MH!4[SWE`*G>>\H!4[SWE`*G>>\H!4[SWE`*G>>\H!4[SWE`8EW<O@:S@U<\G
M4UH*4[*ZUJ@(E]U</VRN`W-]P?BT0'14ZZG4U.NT[SZ4`J=Y[R@%3O/>4`J=
MY[R@%3O/>4!R":C4[1VG>@/'/4;'2=29UK&.D><QDO=:TO<?\Y-V`$J\M.EJ
M-?S5ZCYAF)RXA>6K_B2_:9TP8+*7%"VT=&TBO%,6Q"E:5H[W_@67=A':S-O"
MR+FR#2Z73VU[CXR'E3@,^/\`[%C\5?DBA<;)K[@:DGAO/S,[=NE"L0S[ME_P
MG)>GV'B]Y7PL[\=;M2_X=?\`5HRFY/[/GEMB[.]REEC+ITUK$ZX\/D+^YOK)
MS6&KHV6[WLX*@Z$EU*;%(CQ;,N2C"<E1OD5'VE5D^0_+^-:GDV;<G*,:TE)R
MCIT$):6%CCXN386=K90C7E6L$<#*[RV-K03Z3JMTI2EK)MLAVK%C'CN6(1A#
MFBDEW&4O)M"`(`@"`(`@"`B<C@<)EV\.4Q5C?:<(=<6['R-&GR90!*W9V.6R
M-VY#P2:(N1@X>6J9-J$^M:]NTU_DO)WI2\#W63\CB934M\/<>)MP2>V"[$CN
M$;@]JE0XA?CXJ279ZBBR?*?#+U79=RU)\SJNR5?64#)>2F<@#G8O*V&1:*EL
M5PV6PG<.P`GQ$!=ZW-"E1XC;?CBUWE%D>3\Z&N-<A<7,ZQ?M7>:_R?1?5>(!
M=?X+(,B!(Y\$?C(--2>;:.F:!36IHI4,FQ/PS5>SUE#D\(XIB??V;BCSI;R[
M8U*N202TU#AM::AP];30A;BNK33E!-`3KH*H*L]Q>77V5>G<UT_@NI.I^I<M
M=#-8JPRS<7AX;?'0V\=]!'<L@EO[@7MQ.]D<@:XM9$":T7-Y7'+T+L[-F$5N
MR:JZO8Z;-$?9O+W^,\#,P;'$.(Y-V7QK49[D$HI*232<GO-TK1T2/1W3ODCY
M5]+F.3&]&XR>ZB/$V_RXDS-[Q5!#A+D7SQL<TC3@8VBJ;O$<V]53N/=?(M%W
M'T+A_DSRSPVCQ\2V[B^U.MR7;*J[$;29''&UK(V,C8T!K6,:&,:T"@:UK0&M
M:!L`4.K])TJA&*48I**V):(LF&_03?2M_(6BYXO02\?2+ZR9:YS"'-<6N&PM
M)![PO!(,R/)7<>G-XQ^T'$?PM'?"@)BRR+[IYC>SA<&\7$UYH:4K[IJ1WH"3
MJ=Y[R@%3O/>4!P@"`(`@"`(`@"`(`@"`(!_UJ@-5YWS6Q&-GEM,7:R9B:)SF
M/N!*+>P#VC7ER\$DMP&NTJUH:>PE3+6%.:WIO=3[3GLOS#CV9.WCQ=R:=&ZT
MCZ'JWV&N\CYJ]4WE6VKK+%1G9X2W$LP&[GW9F[PT*5'#LKQ5;_+F*>[Y@XA<
M^[<;:Z%5]KJ4:_R^5RCN/(Y*]O7;KBXED9ZA&7<L#U!2(PA'PI(J;N1D7W6_
M.<WTM^K80MX/\I<!H_5.H`-Q!.@]`7LT-::%).T^LK!D(`@"`(`@"`(`@"`(
M`@"`(`@,FUO;RQ>)+*ZN+21IJ'VTTD#J[R8W-K[5B48R\23/<+ERT]ZU*47T
M-KU%UQ_F7U;84:^^CR,8%.#(0,F<=?\`'CY4]?6XJ/+$LRY*=1:6>.<2LO6:
MG'FDJ]ZHR]8OSAMI'LCS.)?;-.CKJPE,[&_VG6TP;)P[^%[CZ"H\\%K6VZ]9
M;8_F6$GNY5MQ7/%U[GKV,W#:7=M?VT-Y9SQW-K<,$D,T3N)CV'M':"#H0=0=
M#JH,DXMQEHT=+;N6[UM7;34K;V-&0L'L(`@"`MF&TLM?G2R$>D4CU'HJU`2B
M`(`@"`(`@"`(`@"`(`@(S);(?6_XFH"*0!`$`0'RY[6[3[.WN0'49Q\UI]J`
MZS,\]H'J']=4"VFG+YC&9#(.8QC'.OKISBQK6ESG3/)<XM`+B2=I4V+;BJ\Q
MS%V,8Y,Z)*LGZS%63`0$/U#_`+#F/]!-\06RU]Y#]8B9_P""O?RF>?U;'"A`
M$`0!`$`0!`$`0!`$!R"1L)'J*`B,C@,'EVEN4Q./OJZ\4]M&90=XG:&S-/J<
M%LA<N6_!)HB9&!A9?XFU;GUI5[=O>:^R?D[TI>\;K)^0Q,CAH+><7-N-OZF\
M$KZ&NM)`I4,^_'Q4EU_4463Y2X9>J[+N6I=#JNR57WGZ`=$XAV,Z+Z2L&3"<
M673>&M1(YO*=+R+"&/CX*O#>/AK2IHN7OS^)D7)TI6;?:Z^T^Y\&Q7B\(Q;"
M>]N8]N-=E:16I8'M<P\+A0]E=A]1V%:BQ>CH]I\H"Q8;]!-]*W\A:;GB]!*L
M>%]9+KP;P@)3$_O)^C=\80%D0!`$`0!`$`0!`$`0!`$!R`2"0#0:D]@&\G8`
M$!6;SK/H['73;&_ZMZ9LKU[N!MI=9W%PW!=LX3$^Z#FFIV&BVJQ>DMZ,)-=3
M(%WBO"[%SX5[)QX77R.Y!/L;)]LL5S:ON+:6*Y@?$\LGMI8YX7@QD@MFA<^-
MP(W%>$FI4>VI-4H7+;G!J4'%ZIIK9SH\2=I]9^-7[V_ES'RP+`"`X0$=/B[6
M8EW"Z)QJ28S0$G:2T@MU]%$!'2X205,,S7[@]I8::=H+@LC4CY<?=Q;87N`[
M6`/'XI)6`89!!H00=Q!!^%`<(`@"`(`@"`(`@"`(`@"`(`@/5'EM_P`-Q?TN
M0_CIU49?W\O1ZCO.`?VR'7+]J1>5&+DR8K.ZF_1P2$;RWA;^$ZC4!(Q82=WZ
M66./T"LA^``?"@)&+#VD="\R3'0T<>!NG86LH3WH"4:UK0&M`:T:!K0``-P`
MT"`Y0!`$`0!`$`0!`$`0!`$!&9+9#ZW_`!-0$4@"`(`@,%_RW??'XT!\H`AE
M;34>0_?[[_67/_NO4R/A74<S>_$SZWZS#7H\!`0_4/\`L.8_T$WQ!;+7WD/U
MB)G_`(*]_*9Y_5L<*$`0!`$`0!`$`0!`$`0!`$`0%ZP_F+U/AX;>T9<6][96
MS&Q0VU[;M?P0L;PLB9/$8IVM8T`"KC0*//%M3;>JD^8N<3CW$L2"M1E&=J*H
ME)5HER55'WDGG_M#8CIK'V=YU'@+\03Y"&S?/AIX;IT)DAN)3+X:[-L][!R=
M6B0G71>+?"KE^;C:DFTJZZ>HD9OGS&X=:A=XC8GN2GNUMM.FC=:2H^3G)KIW
MS[\INI2R.TZOLL=<OX0+//QS82?B<0`QLEZUEG(ZI^9*Y:KO#<ZSXK;:YX^\
MN[7N)_#_`#SY7XE2-K*A;NO[-U.V^V5(OT29OWINXM\A:2S8^XM[^%TK.&:Q
MGBO(G5C)%)+=\C#4;-=5678RC*DDTZ<NAV6'>LWK>_9G&<&]L6FNU5+7'C+Q
M^IC$8_:.#3^"*N^!:B69T>&;^MF)]$;0!^$ZOQ("2@L[>W-8V>^10O<2YU.T
M:F@K3L"`R4`0!`$`0!`$`0!`$!HKS5\^^G?*S)6^#NL/E<YFKBPCR3;:TDM[
M.SAMIY)8H#/?7',<7R/@=[L<3R`-2-%/Q.'W,N+N1DHP3IJ<CYA\XX/E^^L2
MY:N7<IP4J1I&*3JE63ZGHDSR[G_M<>8&0XX\#B>GNFXB2&RF";-7S14T/-O7
MQV8<6[?S%*JVM\'QX?>.4WV+NU[S@,S_`"1QF]58=NS8CST<Y=LJ+_::-ZA\
MR_,#JOF-S_6&>R$$E>*S\?+:V%'&I8+"R-M9\%=@+#13[6+CV?NX13ZJOM9R
M6;QWC/$:K,R;TX/[.]2/^F-(T]!1>!FONM]XU/NC4G:3IJ2I!441.8;J;J/I
MISYNGL]F,))PN<3C,C=6;'D,=3F10RMAE'H<TA:[EJW=5+D5+K1*Q\_.P$Y8
M5Z[:E3[$G'M2='Z4:VP?VB_,O$B..\O,;U#`PT<W,6#!<O:'$FM]8/LYBXC2
MK@]2[G#L:3T3B^A^QU(.-YRXUC/=N2A>BOSUKVQH_6;LZ5^T[B,M>8_&]0=-
MWN*N;ZYM[,7N-N69"Q;/<RL@A<^"9MO>1Q&1X#J<PM&NJ@WN&3A%SMR325:/
M1_0=+@>>,?(NPLY5F5N<I)5BU*-7HM'1T[3U)PFI%*EIH::T(]2JCN^@X((V
M@CUZ(-FT(`@"`ZY(HI122-CQ_::#W$BH0$?)B+.2I:UT1_9NT_!<'!`8$N#>
M*F&9KAV-D:6GO;Q!9&I'28^\CK6!Y`[64>-E3\DDK`,0@@T((.XC7N0'"`(`
M@"`(`@"`(#*CLKJ459!(0=CBWA;WN+11`2$>$G=0RR1QCM#:O<.ZC?A0:GK?
MRPP]HWHS%&0RS.YN0VNX&_O]QV,`/9O51F*F1+T>H[S@/]MAUR_:D;*CMK>'
M]%#'&=[6CBUV^\:N^%1BY.Y`$`0!`$`0!`$`0!`$`0!`$`0!`=,T#)VAKZBA
MJ"TT(W[010H#`?CC^KD!]#Q3X17XD!BOM+AFV,N&]GO?`-4!CD$&A!!W$4*`
MX0&"_P"6[[YWQE`?*`(96TU'D/W^^_UER?9S7J9'PKJ.9O?B)ODJ_60%WFL3
M8U%WD;2%PVQF4/E]7*CXY*Z;EMC:N3UBFR'=S,6SI=N13YJU?8BM7?7V)A);
M:P7=Z1\[A;;1$_?2DR$?W%NCB7'XJ(K;O'<:.EJ,IOL7?KW%/RW6>1R=O-9L
MAM[.VG:8Y1'QRS21DZL,LAX6AU->%H/I4FWC0@U*K;1597%LC)@[2486Y;>5
MM<U?J*>I!5!`$`0!`$`0!`$`0!`$`0!`$`0&G_.O_BUC_P"<MOX._5AP[[]_
MJG*^;_[?;_G?N2/,5*Z'4'L5P?-3]1/L"@-Z&\P0T`#^;\?H!0?[''N7(^8_
MQ%O^7^\S]`?X=TX1FT_]U#_MGO%<Z?80@"`(`@"`(`@"`(`@"`(#\WOM;?\`
M]0LO_P`AA_XS*KIN#_A'^N_4CX9_D;_]#'_XUOUS/+ZM3@@@.ZWMKF[>([2W
MGNI":<%O#).ZIV5$;7$>U&TO%H>[=NY=>[:C*3Z$WZBUV?0/4]\PDV+;%CF.
MH_(2MM]"TBO*;S)]-W"%HEDV8\M>HL[7`N)7XOW-R--LG3NU?<:VQ?D(P!KL
MWU"\NK5T&)M0UORMGBKMSB:C]D%(EQ/>UA#M^HB8_DU/WLN_KS07ME]!M/I?
MRLZ(Q&2Q<C,1X^XBR%E(RYRD\MX\/9=1.8\1$LM6N:X5%(]"H5_,R)VY+>HJ
M/9H=#@>7>$XM^W*-K?N*Y'63<OM+DV=Q[VX&,+@QC&"NQK6M&AW`!<^VVZL^
MM[L5HDDCY>QD@H]C'C91[&N'<X$)5K8S$HQDJ22:Z2-FPV.FK^8Y3C\Z%SH_
MQ:EGP+9&]..UU(MS!QKGV=U]&GU$7+TV-3!=4W-F97\=A_[5M61^<B)/A>G\
M*>O2OH(J;"Y&']3S6_=0N#^]ONO'<MBNVY<I$N8.3;^SO+HU^LC7QR1'AD8^
M-VZ1KF'N<`MB:>PBM2BZ233Z3Y0P$`0'7)%%**21L>/[303["14("/EQ%I)J
MT/B/[-VGX+@X=U%D$?)A)!^AF:[T2`L/>.(?$@(^7'WD5>*!S@/G1_G!^+4K
M`,?E2_X4GX#OZD!W1V5W+3@@DH>TMX6][J!9%20BPL[OTLC(Q78VKS3N:/A0
M:DA%AK5GRS)-]\>`=S*'X4!GQ6T$/Z**-GI#17\(U<@H=ZP`@/4WEI_PW%_2
M9#^/N%4YGW[]'J.\X#_;8=<OVF7M12Y"`(`@"`(`@"`(`@"`(`@"`(`@"`(`
M@"`^7,8\4<UKA_:`/QH#'=8V\AH&EA/:PZ;#\TU"`K\UH1)(&O!H]X]X4V.(
MVBJ`ZQ:O.US1ZJD_T(#N9:Q@CB+G:CMH/@U0'A[K+)Y&7J3J"VDOKIUO!F<G
M#%!SGMB9&R\F8U@8PM:0UK0-:E=!8MVU;BTE5Q7J/DG$\G(N9U^$YR<%=FDJ
MZ44GS%0WG?J?3ZU(*VB6P(`@"`(`@"`(`@"`(`@"`(`@"`(`@"`T_P"=?_%K
M'_SEM_!WZL.'??O]4Y7S?_;[?\[]R1YB5P?-3]1?L#@_R-Y@FAI_-^/%::5&
M#BJ*[Q5<CYB_$6_Y?[S/T!_AU/\`I&:^3YJ'_;1[P7.GV$(`@"`(`@"`(`@"
M`(`@."0-I`]9`^-`:+\TO)+H_P`T+Z/,Y')YC$YVWQ[,=#>XUT%Q;/MX))9;
M=ES8749CD,3YGZQR1.(=J=`IV+GWL6.Y%)VVZT?/UG*<?\H</\P7EE7IW+66
MH*.]&C5%5JL7S5>QH\ZW'V2\C;S/D@ZIM\K;-<2R!MI]57;V4J`^2>6]M@^H
M[#16/]9A+1P<7SUJ<9/_`!G?MO>CDQN0YMW<E3K;DJF$_P`F&].4?=]*7D_`
M?WJY#\I`2!MK;NDM0/6T!>_GOBZ*:UY-AY7E2U@>]=QINGVI5FNZJ[CNBAAM
M6<J"&*U8W3E11L@:*::L8U@'M"Q7>VNIOC"U;6[",8I<B5.XE['"Y?*'AQV,
MOKPD.HZ"VE='H#ME+1$T>MP7B4X1\32)5K'R,A-6(3GIR)T[=A7K+RVZBNB#
M<BSQT9)J;B<32@?0VPDU];@LO)MQ5%5LT6N"YMRF_NP72ZOL1=<5Y9XZRFAN
M;W(75]+!)',V.)C+2WXXW![>+6:9[0]H^<VO:M$\J4E2*2+*QP.S;DIW9RE)
M-.BT55VLV6=37>HI>!`$`0!`?+V,D'#(QDC=SVM>.YP(1-K88E&,U2:373J1
MLV&QTU3R.43K6!SH_P`4$L^!;5>N+ET(L\'%G]G=?1I]1%R]-C4V]T1N;,RO
MX\=/R5L61SHASX7_`-*?:O:OH(N7"Y&*IY`E`[87M?\`BU#_`(%M5VV^4BSP
M<J'V:KH=2,>Q\9X9&/81V/:YA[G`+8FGL(C3BZ233Z=#Y0P$`0'-3O/>4!P@
M"`(`@"`(#U-Y:?\`#<7])D/X^X53F??OT>H[S@/]MAUR_:9>U%+D(`@"`(`@
M"`(`@"`(`@"`(`@"`(`@"`(`@/IGRA[?B*`@9OTLOTC_`,HH#K0!`:OZM\J.
MGNJ;F;),DN,/E9Z.GNK-K)8+IX`',N;.0M:Z4@:O8YA=VU.JEV,RY96YXH?E
MRG/\2\N87$+COIRM9#VN.J;YVGR]*I7E-093R-ZIM*NQ=[C,Q&!HSF/Q]R=P
MX+GC@)/TJG0XA9?C3B^U'-9'E/B-K6Q*W=CUN+['5=YKG*](=480GZTP.3M6
M`G\_X9\]L::$BYMN=!P^MP4JW?M7/!),I,CAV?B?B+-R*YZ57:JKO*Y4'MV;
M?1ZUM(50@"`(`@"`(`@"`(`@"`(#Z:USW!C&N>\[&,:Y[S7<UH+BC:6KV&4F
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M]KYB5Z2^P0P/M[CKGS`$L0+'SXSI+&N87B@+H1F<JXEOO5'&VT.FHHLWO,>C
M6/;UYY/V+Z37PW_#M)1GQ?,JN6%F-/1OS]:@>[>BNB.F/+SIZSZ7Z1Q<6*P]
MF7O;$'/FN+FXE-9[V_NY2Z>\O)W:ND>2=`!1H`'.Y&1=RKKO7G6X_P`M%R'U
M_A7">'\%PH\/X;;5O%CR;6V]7*4GK*3Y6^K9H6M:2Q"`(`@"`(`@"`(#JDFC
MB`XSJ=C1JX[=:=@T[4!B.OON(_:X_P!`_K0&.ZZF=\[A&YHX?AVH#H+B[5Q)
M.\DGXT!P@"`Y!(V$CU(#`FQF,N91/<8W'SSBE)IK*VEETV?G'Q.=IV:KTIS2
MHFZ=9IECX\Y;\[<'/G<4WZC,=I&YHH&AC@&@4:`&F@#10`!(^)&W9&BV4-)'
M:?6I9S+VLX63`0!`$`0!`$`0!`$!\O8R1O#(ULC?N7M#V]S@0LIM;#$DI*DD
MFNG4C9L-CIOU'*-#[T#C'J>WAU8>Y;%>N+EKUD2>!BSUW=U]&GU$7-TWM-O=
M>IL[*_CQT_)6U9"^TB)/A;_Y4^U?1]!!7=A<V)`G91KC1DC#Q1O.X.TH?00"
MMT9QGX60+V/=QW_$6G/R,PUZ-`0!`$!B7M_8XV(S9&]M+"(4K)>W,-LS4T&L
MSV5J=R]1C*6D4V^@UW+UJRMZ]*,(]+2]8LK^QR40GQU[:7\)K26RN8;IFFW6
M%[Z42491=))I])FW=M7EO691G'H:?J,M>3V>IO+3_AF+^ER'\?<*IS/Q#]'J
M.\X#_;8=<OVI%[44N0@"`(`@"`(`@"`(`@"`(`@"`(`@"`(!MT&J`C<GFL/A
M8S-F,KCL5$-./(7D%K4TK1K97M>\T[`"5ZA"=QTA%M]"-&1E8V)'>RKD+<?T
MI)>LUED?/+H*RDY.-N<CU+><7"VUP..N+@/<0:`7%P+>`@G2K2[53(\/R'K.
MD(\\F4-[S9P>$MS'=S(N<UN+?>Z+LJ0]]YC9%[&308)^-%Q&V<#)\U\\9E`=
MP.8QL$8<VM"*G5>8XT:T<D^H]3XW?<%*-EV]Y)^_6JKR4TU15+KJ[J*[=5V3
MFA&ON6C66S`#]&T//M)6U6;2Y$0+G$LV[MN-+]'3U&%'U!G8SQ,S&1!K7WKJ
M5X]K9'.:>Y>OAVZ4W4:UFYB=5=GVE@L^O\];T;.;6^8*5Y\/*E('[6W,>OI+
M2M;Q[;V51+M<8R[>D]V:Z51]J^@M5GYCXZ3A;?6-U:N-`Y\#F7,(/:>$\J4-
M]A*TO&DO"TRPM\;LRTNPE'JHU[&6JSZEP5]06V4MN)U!RIGFUD).@:67`CJ:
M[JK5*U<CM3+"UGXEW2%R-7R/1]C.C*=(=+9L.=D\!B[MTE:W(MF0W!)%.(7=
MMRIBZG;Q%(WKT/!)H\9'#>'Y>M^S;E)\M*/M5'WFN,GY&]+W7$[&7V5Q,AKP
MM,D>0MP?2RX:R<-_]52X<0O+QI2784>1Y2P+FN/.Y;?-7>7?KWFM\IY'=56G
M$_&W>+S#!L8V5]A<D;^7=`P'U"6JE0XA9EXTXOM*3(\J<1M:V)6[JZ'NOLEI
MWFN<ITEU/A*NRF!REI&#0SNM7RVW;KXFWYL%#3[I2H7[-SP23929'#L_%_$6
M;D8\]*KM55WE>!!V&O\`7N]:W$*J"P`@"`(`@)G%]/Y?-!SL=9NFB8[@?</>
MR&W:^E>'FR.:'.IV-J0M=R];M>-DO&P<K+J[$*P7+HEVLN]EY97C^%V0R4$`
M^=':1.N)/4))>5&.YRBRSHKP*O66MKR_=EK?N1BN:*J^UT1;;#R\Z?@+0Z"Z
MR4H[+B5SVD^F"W;$TCT&JCSS+KV-)%M9X'A1:K&5R72].Q41?<?TQ);-#++&
MV]@S0<0CAMJC94A@$KM-XJHLKKEK.3;+FQPYVU2U;C"/0DOK)Z'IP[;FZ]D#
M*GTU?(?^U:_B<R)L<#\^782D.&Q\-*PF9P-:SN,FO9[H#6:>I>7-OH)$,2Q#
MDKUDDQC(F\,;&1M^Y8T,'<T`+S6NTD**BJ122.UFWV?TA#)D,DDC-6/>S[UQ
M'Q(#,9DKEORG-D^_:*][>'5`9C,JPTYD3FFE*L(</70\)^-`9T-Q#/7E/#B!
M4M-0X"M*\)H2*H#O0!`$`0!`$`0$/=5Y[Z[Q3U<(0&.@"`(`@"`(`@'_`%KL
M]M=$!KC(6O3DLLC[7)>%?Q.XHO#7,]OQUUY;F15:TG<7#<I,7<2]Y512W;>$
MW6W.CYJ-KU%=FBCC-([F&X&^)MPWVTG@BHMFTARBD]&FO3[4CH63R$`0!`$`
M0!`$`0!`$`0$7FO]LGV?*@I6G^,S97MI5;;/WBKL(?$*?*2Y]*==2A*:<\$`
M0'GSS*/FT[,7HZ?&69TVV.W%H<+X3GO)MHS=&3PI?E*BX+Q[P:*`4TH398OR
M>XOB[OQ>GZ]#D^+_`->^8E\K\3Y2BIN4KLUK3WMM=OH/,M_]8>(/UKX[Q=37
MZS\3XFM=:^+_`#NU6L=VGN4IT?4<9=^)O_Q][XGZ5:]YW8F.^ENV-QD]S;W-
M122R&0,PU%*#&0SW.W^S18FXI>^DUTT]I[L*Z[B5AR4_T:U_VZGL?RAQ?58S
MV-=UYU/F']*$7!OXKG&7(N`!:R.M6Q7%[:#+CBN0P$QQ.T)V;529T[7PY?+P
MC\?DU^AT/H'EZSG?-P_JUVY_3Z/>K%UV.FK6_MIL3/T=POU5]56/U'R/JKD#
MP7AZ\OE<1XC[U'\PR5X^+WN.M=:KE[F_OOXE=^NM3[3B_+_+P^5I\O32FS\N
M>NM247@D!`$`0!`$`0!`$`0!`$`0!`$`0!`1N1OKJRB+[7#9',24J(;";$P&
MOW+I,ID\>UM?1Q+W",9/WI**Z:^Q,T7KMRU&MNU.X^:+@OVYQ-79GJCSAEYD
M?3WEG9V;3Q-CNLQU+@KR85T:_P`+:Y6U@:X;:&1X4N%G!6MV\WU1:]E3G\G/
M\S2K'#P(Q7(YW;<GUT4TO15FENJG_:+EAEDRD6=M[,AQDAZ;^KS"UG#[P<>G
MYKFYX`S[IY4^S_2TZ0W7+]*O[VARW$7YWE%N^KT;7*K6[3_PVWWE&Z-_E'BO
M#UP:YOQ@%LW._6%?#<AE3+SP(>(S<5>::[-%MR?CZ?*_=T^S3:0>"_T>DWQJ
MGSF_I\3>V46VNE:UVF_L7]4^'9]3?5WAN$</U;X;E\/I\-IWJHG\3>_B5WND
M[[&^4W%\G\+X=/L;M*>@M+"TP-YH:UG``>:6%A%!J>+W:'TKR3G3=][P])4\
MO_+9@N.'P@O.5)R3;<53-PG@#N0#%\K[K1;8?$Z:?ESE9E?T_<E3<^-32G/Z
M-"AJ04@0!`<&E-:4].Q!IRD[A_YCXA]2G*C9^Z\_DTK\ZH,%*[UJG\+[>[4E
MXWSM?_+?$]%:?0;%LKKS$MPWQ&,MK^.@%+B;'P3=FI?#=QN!];2H\EC/8VGZ
M?H+NW<XW#QVXS72XI]S]A:K/(Y66C;[I^ZM'=KX;[&747<;N&4=Q6J48+PR3
M]#^@L+5[(EI=LRB^B46O6B<;Q%I(#@*>\#L`IJ'4);0=O8M9*Y.@UKU4?*RK
MOYG'31G+75+>7]8@5%?]L/C>*N^I4JS\W_RM^G=WZ%#Q'_Z]_P"O^!O_`.[_
M`&>\:7RF'\E[OB=BNK<IB)-:,=C,QD+:O91ESC&7'"/1*5/A<SX^*$9+K2]I
MS&1B^5KNN/DW+4OU)R7?&O>:XRF)Q-F7.QO56,R\8KPM;C\]87+@-@,=UC/#
MAQ^EIZ5+A.Y+QP<?2G[?84>1C8]I_P`#(MW8_JW(OL<*=Y7UL(80'?;PLFD#
M)+JWM&G;-<BZ=$WUBTMKJ8^QBQ)T6QOL]K1[A%2E1RC%<[K3N3?<>C^@L?B(
M.GK=GU_!?1^)NG<ZRL<C''QN>"Z,>/M+>:K-A/+`/8J?+E)WF]UI]:]C.[X'
M8Q88"B[RFMZ6L8RIMV>\D^XV'`WIUI`XVR.^ZN><!W/9''\"B_Q"_MK`6QUZ
MZ^TL4/(X!X?D\'9R>7P^WEZ;%K=>7:3H[M/<IN]!VK!Z"`(`@/MFW;V;/:/8
7@.U`$`0$CC?WD?1/_*"`GT`0!`$!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g52781tx_pg03a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g52781tx_pg03a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`C0+&`P$1``(1`0,1`?_$`.```0`!!`,!`0``````
M```````%`08'"`(#!`D*`0$``04!`0$!````````````!0$"`P0&!P@)"A``
M`0,#`@,"!@@/#00(!P$``0(#!``%!A$'(3$2$PA!46%Q(A2!D;$R4Y34%?#!
MT4)2LB,S<[-4E=4V":%B<B0T=+0U5746=M9#9+66X6.3TT0E%S?Q@I*BPF56
M&1$``@$#`00%!P@(!`4#!0````$"$0,$!2$Q41)!87$3!H&1T2(R(P>AL<%2
M<K(S%$*2TG,T%34(\.%B=(+"4],6DR08HD.S)1?_V@`,`P$``A$#$0`_`/W%
M$G4\3S/A/CH"FI\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\
M9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@/+.
M),*5J3]Y5[HH"R*=72"Q<DW!L>/A<=M8NER&J?5(KB>S94"/Y5)!4AK16FJ4
M]2_(*V+6-<N;7ZL>+(C.UG$PV[<7WE_@MWE9@'(<QO>2.'UZ1V<1*^IFWQ]6
MHK1'O2I(]-]P?9+)/BTJ3M68652&\Y#-U'*SI/OG2W]5;E]+\K+8ZC]!5]6L
MIH#J/T%7U:`=1^@J^K0#J/T%7U:`=1^@J^K0#J/T%7U:`=1^@J^K0#J/T%7U
M:`E+5?+I99(EVV8[&>X!72=6W4@Z]#S1!;=1KX"#Y-*LN6XW(\LMQL8^5D8E
MSO<>3C/_`!T;C.F.;IVZ?V<6^-IMDHZ($M!)@.JY`KZM5Q"H_9%2>/,5'7,.
M4=MO;$ZO"\06+S[O,7=W/K?HM_1\IE5"T.(2XVM#K:TA2'&U!;:TGDI"TDI4
MDCPBM-IIT>\Z%.+7-%IQ?2MS.5"HH!0"@%`*`4`H!0%UV0GU-?X97N-_5H"6
MU/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`U/C/MF@&I\9]LT`
MU/C/MF@&I\9]LT`U/C/MF@&I\9]LT!Q4X$#J6OI3XR3[0',D^*@(MZXJ/HLZ
MI!YJ(]/SIUY:^7C0$<5*))*E$DDDDDDZG7B:`IJ?&?;-`-3XS[9H!J?&?;-`
M-3XS[9H!J?&?;-"JWFG>4_K+D!/]L7#^DN?4J<M?A1^RCS'4')ZC>BG3WDOO
M$#P\OM_]%9#4Y9_6^0QYE^V..YAUOK:7;;ROWET@)`==5]:F9'X-S$C3GZ+F
MG)0K;Q\R[CO8^:WP?T,@-6\-8&JMSDN[S7NG'>_M+=)?+UF'QW?,HM\LN9%*
M:BV3K"6)L'K7(F!0)2GL70/F]9_ZW4Z^]!YUOO5;4XTM)NYP9R*\":CCW7+-
MDHX==DHU<I+K7Z/E,L63'K1CL7U2TPVXR5=)>>)+DF2M(.BY#ZR5N*U/+@D>
M`"M*Y<N79<TW4ZG#P,73[7=8L%&/2^E]KZ2:JPVQ0"@%`*`4`H!0%G9-@MAR
MA)<E,JB7#IT1<X>B).H'HA]/WN4@<M%#73D16:UD7;.Q;8<")U/1L+4TYW8\
MN1T3CL?EXKJ\QKKD^W^18R5OK;-QM@)*;C#0M24)_P![8U+D8^4ZH_?5+V<J
MU>V5I<X,X#4]"SM.DYR7>8]?;CM_66]=NXL3M%>`ZCP'CQ_=K9(0IVJ_'[OU
M:`=JOQ^[]6@':K\?N_5H"?QO&LDS"Y-VC&K3-O$]9&K41I2D,))T[67(44QX
MC">96XI(TK%>OVL>'/>DHKK-_3],U#5<A8FG69WK[Z(K8EQDW2,5UMHW@VX[
MJ=KMACW7<68F^3D]+B<=@NN(LT=0T(1/E>@_<BGPH2&VM>'I"N<R];G-.WBK
MEC]9[_)P/9O#WPOQ\?ER=?FKMU;>ZC^&OM2WS[$DNMFW4.)%@16(4*.Q$B16
MD,QHT9I####*!HAIIIL)0A"1R`%0,FY2<I-N3WM[V>JV\>U9MQM68QA:BJ))
M)))<$BZK.?N#_P"&3]H:P7/:\AO8RI%]I--NN-+"VUJ0H>%)TU'B/@(-6&R3
ML:[A6B9&J%<!VB2>@^521[TZ^Q0$N%]0!2OJ2>(4E6H.OB-`5U/C/MF@&I\9
M]LT!4$Z'B>7C/C%`4/,^<^[0%*`4`H!0"@%`*`4`H!0"@%`*`4!:66Y79,;M
MTLW&4/62PKLH#'2[,>/`C1K4=F@_9+*4UEMV+MSV5ZO'H-',U'$PHUNR]>FR
M*VM^@U0R;<>]7P+C13\TVY1*2Q&=5ZR\C7@),E)2O0CFE'2GSU(VL6%O;+;(
MY#-UO*RTX0K;LOH3VM=;^@QV3KS^CQD^$DUM$0W4I0H*`4`H!0"@%`*`4`H!
M0%U8]F-[QQQ(@R.TB$_=($DJ<B+'(E*=0IA>GUR"D^/6L%W'MW526PW\/4<K
M!E6S+W;WQ>U?Y>0SYCFX-DR#LXZUBV7)6B?5)3B>S>5IRB2?1;=.OUIZ5Z>`
MU'7<:=O=MCU(Z_!UK%S/4F^2]P>Y]C+[K7)<4`H!0"@%`*`4!=5D_D;GX9?V
MK5`2U`*`4`H!0"@%`*`4`H!0"@(VY'T61^^43Q/$@#0^P#0$30"@%`*`4`H!
M0JMYI[E/ZRY!_?$_^DNU.6?PH_91YCG_`-2O/HYY?>.NW6*;<-%A/81R?OSO
M#J'_`%:."ED^`\!Y:3NQCNVC'Q;]_P!:G+;X^A%]V^S0;:$J;0'7]"%2'=%.
MZ^'IT'2V#Y/;K7E.4MY,8^):L[4JRXO>=61MH=L5U2XD*"8;SH!&NBVD]HA0
M\1"A5;5>\36],IJ$8RPKO,JTMM^;::^U*G""@%`*`4`H!0"@%`*`<]00""""
M"`001H00=00:#?L,793M99+[VDJV]-DN*B5=3#85`D.'77MXB=.R)/US>GE!
MK;LYMVUZLO6A\OG.:U+PUA9C[W'2LY#K[*]5OKCT=J->,@Q2^8P]V5VAK;;4
MHAF8UJ["D#70%J0D=/41]:KI6/"*E;5^U>5;;J^&YG!9VFYNG3Y,J%(O=);8
MOR\>HMRLQI--;RA.@)\0)H49]=]F[%:;%MKA[=J@QX9N./VNY7!UEI"7ITZ;
M%:DR)4MX)#C[BG'3IU'1*=`-`*X//N3NYEQW&W2;2X))M?0?57A+!Q,/P[B1
MQH1@[EB$YM+;*4HIN4GO;=>G<E1&3JU#IA0%Q6;[P]^%3]I6&Y[7D-JQ[+[2
M7JPSB@)6TN+$@MA1Z%-J)3KP)!!!T\!H"XZ`4!4<CYOIB@!YGSGW:`I0"@%`
M*`4`H!0"@%`*`4`H"/N=VMMEC*EW28S#8`5TEQ8ZW5`>\8:&KCR_(D&KX0G<
M=(*IAOY%C&CSY$E&/ROL728-R7=>;,[2)CS2K?&/4DW!X(5.<2=1JRC13<4>
M(GJ7YC4A:PXQ]:XZOJW'*9WB"Y=3MX:Y(/8V_:\G`PU<GG7V);S[KCSSB5*<
M==67'%J)!*EK62I1]FMU))4CL1SC<I2<Y-N3WMNOSEC'F?.?=H4*4`H!0"@%
M`*`4`H!0"@%`*`4!77EY#J/&#IIJ#SIOW@R'C6X]ZL0;C2E&ZVX$)]7D.$2&
M$#0?Q:20I8``X)7U)\U:UW%MW-L?5D3&#K65ATA<K=LKH;VI?Z7Z>PSW8<JL
MF2-`VZ2/60D%V"^4M2VO&>R*CVJ/WR"4U&W+%RU[:V'7X>H8V:JV9>M]5[&B
MXO\`X?1XZQ;]IO"@%`*`4`H"ZK)_(W/PR_M6J`EJ`4`H!0"@%`*`4`H!0"@%
M`1ERY,^=?N)H"*H!0"@%`*`4!Q4M*.9]CPT!@"=8X2+[=ISJ?67G[G+>2ET`
MM-=;ZE)"6^*5*3XSKQ\`J2C<;MQCT4./N8EK\Y=N2VR<Y/;T5?\`C:>LG7P`
M:<.`TH9DDMQ2A4B;_P#U'=O[OE?BC5]KVUY/G-//_@KW[I_,S7JI4X,4`H!0
M"@%`*`4`H!0"@%`=3[#$IAR-*8:DQG04NL2&TNLN)(T(6VL%)%$VG5-U+;EN
M%V#MW8J5M[TTFC"N4;/19!<EXP\F&Z=5FU25J,1:N93%DGK7&//1*^I/E`J0
ML9\HKEOJJXK><=J/A*U.MW3&H3=?4E7E\DN@P%=+5<;/)<A72&_!DI!^YOH*
M>M/'1;2_>/-GP*22#4G"<+BYH.J.(R<>_B7'8R8N%U=#^CBNM'U^VS_]N<#_
M`,HV#_AL>N$R_P"+O?O)?>9]7>&_Z#A?[2U]R)>]:Q."@+BLWWA[\*G[2L-S
MVO(;5CV7VDO5AG%`25J_E8_!K^E0%S4`H"HY'S?3%`#S/G/NT!2@%`*`4`H!
M0"@%`*`4`H#%N;[B#'WU6FTMM2;HE/\`&GW=5L0"M(4ELM@CMI720="0E.O'
M4\*W,;%5U<]QT@]W^9`:IK?Y27Y?%2E?6]O<J_.S7VX7.X7:0J7<Y;TV0O75
M;RRH)!.O2TC@VT@>!*0`*DXQC!4BJ(XZ]>NY%QW+TG*?6>*JF(\L[^22"?`V
M?I4!91YGSF@*4`H!0"@%`*`4`H!0"@%`*`4`H!0':T^\PXAUAUQEULA3;K2U
M-N-J')2%H(4DCR&C2:H]Q=&3C)2BVI+<UO,R8ENA*0['MV1J$AA92TBZA.DA
MA1(2A4P)T0\SJ>*P`I(XG6M"_BK;.WLZCI=.U^XI1L9OK1>SFZ5PKQ7%[S/'
M`\4D%)XI(.H(/$$'P@BH[MWG7=FX4`H!0"@+JLG\D<_#*^U;/N"@):@%`*`4
M`H!0"@%`*`4`H!0$9<N3/G7[B:`BJ`4`H!0%"0.)X4!T+?YA'#P:\?<-`=!)
M)U)U/EH#$MS_`*QG_P`\D?C%5OP]E=AS5_\`B9]K^<\-7F,4!$W_`/J.[?W?
M*_%&K[7MKR?.:>?_``5[]T_F9KU4J<&*`4`H!0"@%`*`4`H!0"@%`*`C+O9[
M7?8BX5VA,36%@Z!Y/IM*(TZV'4Z.L.`<BD@U="4K<N:VVF:V7AXV;:=G)A&<
M*;*]'6GO3-P\1M+=NQ#%H40N&/$Q^U1V0XKK=#;,-EMOJ5H.L]*>)X&H&_)R
MOSE+VG)M_.>LZ5CQQM*QK-GV86(17&BBOH)KEP/,5B)"O04H"XK-]X>_"I^T
MK#<]KR&U8]E]I+U89Q0$E:OY6/P:_I4!<U`*`J.1\WTQ0`\SYS[M`4H!0"@%
M`*`4`H!0"@%`<5J*$.+'$H;<6`>1*$%0U]JJK>6R;46UO29I-)D.RY,B6^HK
M?DO.ONK))*ENK*U$D\3Q5PUJ>244HQW(\OG)W)RN2VRDVWY6=-5+!0'4\@.-
M.-JY+0I/M@Z>?C0%D.M*9<6VL:*2H@CW#R`T(-`==`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!2E=X-L<!FO3\1M#SZBMQMMV(5DDJ4F(^XPV5$\SV:0/8J'R8J-
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MM'-'LH!0"@%`*`4`H!0"@%`*`4!&7+DSYU^XF@(J@%`*`4!Y7EDJZ>`"0!P\
M/(ZGRT!TT`H#$US_`*QG_P`\D?C%5OP]E=AS5_\`B9]K^<\-7F,4!$W_`/J.
M[?W?*_%&K[7MKR?.:>?_``5[]T_F9KU4J<&*`4`H!0"@%`*`4`H!0"@%`*`4
M#-Q<7=;>QG'UM+2XCYIA-]22".MMA"'$ZCZY"TD$>`U!7?QI]IZWI4HST^S*
M+3CW<?D23^5'OEH`*71PZE=*@.7`:Z^SI6,V+RI1QV'DH6%Q6;[P]^%3]I6&
MY[7D-JQ[+[27JPSB@).T@F5KIP#:M3QX:Z`>V10%RT`H"HY'S?3%`#S/G/NT
M!2@%`*`4`H!0"@%`*`4!UO?>7_P#WXI=56]=I;/V)?9?S&D53YY8*`4`H#QR
MH3$H?=!HO0A+@X+3QU`Y:*2/$:`MR5;GX^I">T;UXN('+^$D:E/[HH"/*2GG
MIQH"E`*`4`H!0"@%`*`4`H!0"@%`*`4!M-MI^IMM_#S_`.F/5$YGX\O)\QW^
MA_TNWVR^\R^ZU26/CI^VT[I5Y[RW=*<S;#!=)N?=VV?=]SK7C<%<EYC*<1EV
M]B#N#;T6QHJ1*OEKL<)%QA+2@N],1]E/!\UR_BS399VG=_:J[UA\R2Z8O9+9
MQIM73P/J+^T[XD8O@;XC/1M4[N&DZ["&+*[)*MJ\I.6.^?HA.;=J:;I6<)/V
M#\.T-F1<)$.';HLFX3KA(C0[?!A1W)$N?,F/(8A0X;"$J7(DS'W4H;0D$K6H
M`<Z\GKS>K%-M[$N)^LMQPLPE=O24+4(N4I2=%%159-M[DDFV^A(_5WC7>%RC
M]D)L=LAW4L(L>)Y[OC-Q^7O'WCDYI-O=QL^`9IN2B%<;1M]C\*TW2`W`FV2R
ML-B8->A:@E[IZI"E5]5_#7X<PRM![[4YWK<7+9RM*LOTMZ?JK9'9ODFS^9W^
M_?\`O8R+7QNO8_@;$P<NW:M1MRE>4Z1L0JL:O=SBW=O+GR)<S?):G9A2ANKW
M"?VL64]Y+>]K9G>G%L!PQ[++/).W=VQ/YYBHG99;B9;V.707JZ7%+CMWM:7%
M0BWT$OL]F>HN)TZ#Q3X$L:-ISU'3KEVY&$UWBG1M0>Q27*EN>_8]AX1\#?[I
M=3^(GC1>$/&&+@X=S*LO\K.QWB4K\?6=F:N3E5W(*7=TH^>/+MYE3[BD:5YH
MMJ/M);54I0"@%`*`4`H!0"@%`*`4!&7+DSYU^XF@(J@%`*`4!XG/?J\]`<*`
M4!B:Y_UC/_GDC\8JM^'LKL.:O_Q,^U_.>&KS&*`B;_\`U'=O[OE?BC5]KVUY
M/G-//_@KW[I_,S7JI4X,4`H!0"@%`*`4`H!0"@%`*`4`H"XL?RJ]XT]UVZ42
MPI?6[!?U=AO:\^MDD="R/KD%*O+6&[8MW5M6TD,'4\S3I<V/+U'OB]L7Y./6
MJ-&;+=NIC,]F+'N\EC'[A*D,QF6[@^VW#E2G$N%#,28YT-]HYV9Z4+Z5$C0:
MU'3P[T&^1.44JNG0CL<;Q-I^1&,<J<;-Z3HE)TC)NM%%OI=.DOOR^`\0?&"`
M01Y"#6L3R:>U5+BLWWA[\*G[2L%SVO(;=CV7VDP`5'1())Y``DGS`:FK#.2\
M:TN*/7)/9H^#&A<//F>2/W30$XTRTRGH:0$)YD#PG3F22230'90"@*CD?-],
M4`/,^<^[0%*`4`H!0"@%`*`4!$WN_67&K<]=K_=(5GMK`)<ESWT,-Z@:]FT%
M'M'WE`<$-A2SX!5]NW.[+DMIN74:V7F8F!8>3FW(6K"WN3IYN+ZEM-4+[WP;
M'$O'JU@Q29>;*V[T/W.7.%LER4]72MR!;_5Y&C9'%/;*0H^$)J5AHUR4:SGR
MSX+Z6>=9?Q+Q+63R8>-*[BI[92ERM_9C1^2K5>E(V`PK=##-QK:Z_C5U;<F)
MBO+E66641KS"^Y*ZNVA*62ZTD_[1HN-GQUH7L6]C2]XO5KOZ&=EI7B#2]<QW
M/!N+O>5UMRI&<=G3%[^U5J:QU+HX84`H!0"@%`14NULO]2T?<G#J24^\/+WR
M.7'3F.-`6[(AOQ3HZ@Z:Z!8!*%>+17+CXCH:`\U`*`4`H!0"@%`*`4`H!0"@
M%`*`VFVT_4VV_AY_],>J)S/QY>3YCO\`0_Z7;[9?>9D%EAZ0L-LMJ6K4`@#@
MG7PJ)X)'#PUJDL8H[R&\.,=V/8W/]ZLQ+4UK%+0L66QEU+/^(\LNBO4,9QME
M1T+J[I='D!W3@F.EU?%*#4IHNEW=:U.UIMG?<EM?1&*VRD^Q;N+:1Q'Q'\<Z
M?\-_!>=XPU%UCBV_=PK1W;\_5LVH[:UE-JK6U14I=!^8%G]KSWN8[K4ABU=W
MUAUEU$AE+.QV+-!I;3@<0AE]"DR&PV4@)6E0<&FH/57LW_\`-?"RI2%ZJ6]3
M2=>-%$_.-_WJ?'R5>?/PW&6].Q)II[T_>[5T/J-;.^`%97N'$[QL.XS+EB/>
M=B2]S+9,N<U4V9C^8-OMVK<G;2XS'"-9>`9.RIB(@Z*59'H#@&BQ70>'VK&+
M_)Y14;^$U;:2HI0=96YI<)1]KH4U)=!X]\5ZZGK\?B!9G.[I?B.,LN$I2YG:
MOI\F7B2EL];%O)Q@J+_V\K$J)2+;[K&,L7K=.'GETO-PQ[`]BXJ-Z=P\GLLO
MU2ZVVQX5<(<JUV:PSDDI8RO-\G5#LUK',R9G7H4MJK-KE_N\)XD8J>3DONH1
M>U-R3JY+ZL(\TY/@C1^&>FPR_$L->RKUS'T/1(_S#*OVW2<+>/*,H6[4ENO9
M%[DL6>GGN<U*19N]</VU'?;F3Y\J#.VKM<27,ER(5L.W4*;\VQ7WW'(L`S7I
MX>F&"RM+9=6`ISHZCQ-<U'X;^'(P49+(<TEM[QJKXTIL3WTKLJ>SY']XWQEN
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MU9_AW=,VZVM:P=6_V_VQ%EWOW!SO++3,EX)M/@4:T8^UD.9'#;//@2[_`'O(
MLMOR+?8K3ZY&C%Q+KCSO9,E*JI*C;Z`=.Z&8]Z;NA6F'O-N)NWC/>1V)M-_Q
M^#O197MJ;-M?N'M[B^17F#87=Q<$NN+7FX6B^VG$YMQ:>N%KN+';*AE:VY'4
M@U1)-T0,S=TW>',]S(6\N";H2[1/W:V&WPS#;+*)ECMK=FMU^QF4XSE.U.70
MK4TMUN.QD^W]YB+*D$H<?:<4/"`=.@&M1[Y6[M^RG=:W[9V/$\L>S3O.O=U+
MNGV.\L/0,?7<]KL2=N^_^].X%_MJU7>[X1B%Q8EA,2+T+<5"3';6E;Y6E0&1
M=QK9WZ=EL/ON[]IWOP'O$JPFU2\JS'8R?LE;-M8F48Y9HR[ADEMVPS*P9+>+
M]9,FCVN.\[;479-P9E.MI:=*2O6J['L0.^X]Y#<3?S-<&VR[I5QQ#'8M]V5P
MC?\`W$WHW`QZ;E\+`<)W-[8;=8CCN#PKI98^0;C92S#E25^N36H-OAQ2M:75
M.(35O:#,>+8[W@=MK'N1?MR=^[%O';;=@=_NV+QCLW8MNKO9<DM%KN%R3*FW
M#'\BN,"]69UN,E'JRXK3B5:DNJ'"J^KU@Q3W8X_>NW5VJV'WMS'O'X\]:MP<
M(P/<3)<$MW=UQ>VL+AY%:X-WN.-0<K1ECD^&WTR2RW-#"G$C1?03PJLJ)@QA
MM)WMMVGN^#N3M1NPK&'=E,JWDW2V3V&OUILR+5<\8W*VGL^/98]@F97-+RV[
MO,S_``^_O2[2XL-N+>MCK:0KJX5<53KH#93!-T,LRKO%=Z';*\/6]S%=HU[)
M##6H\!N/<&1GVWKF29#\Y3TK*[CVET0"SU!/8M^B->=6TV5!GVJ`4`H!0'B<
M]^KST!PH!0&)KG_6,_\`GDC\8JM^'LKL.:O_`,3/M?SGAJ\QB@(F_P#]1W;^
M[Y7XHU?:]M>3YS4S_P""O?NG\S->JE3@A0"@%`*`4`H!0"@%`*`4`H!0"@%`
M8FWF`.'L@\1\^0/Q$VMW3_QW]E_0<QXM2>EQK_UE]V1:VVW>$S?;[L+>^\K)
ML;1TH-GNS[BGHC0X$6JY'M)$0`<FU=HUJ/>CG6;,TK'RO6CZEWBNGM1&>'O'
MFM:%3'NR_,Z<MUN;=8K_`$2WQ['5=1]-MDMP+#NW8KE>,>1/B-6VX1X5SC7)
MA+;T:8]$$D,LK;<=9EH#:O?I(3KX->%<AGX=W"NJ%VFU;*=)]!^%O$6#XCPY
MY."KB[N:C-323C)QYJ53:?:C/L>(S&'W-/I>%P\5GV?`*T3J#TZT`H!0"@*C
MD?-],4`/,^<^[0%*`4`H!0"@%`=;SS,9EV3)>:CQV$%U^1(=;889:3Q4X\\Z
MI+;:$CPJ(%$FVHK:V4E*,(N=QJ,$JMO8DNMFJFX_>GQW'R_:\#99RF[)"FU7
M9U2V\>AN:%)[(I*)%V6@_8=FT3]>:E\;2KD_7R'RPX=+]!YUKOQ!PL-O'TF*
MR,C=SO\`#79N<Z=5#17+,URC.+DJZY1>)=UDZJ[%#J^B'"022&8$)'3'B,I!
MTT2G4^$D\:G+5FU8CR6HI1/)=1U34-6OO(S[L[D^A-^JEPC'<EP^=EK5D-`[
M6)DNWNIG0)4F#,C)<<CRX;[L:0RL(40IIYE2'$'4>`U6D9+EFJQX%8W;EB7?
M692A>C6DHNC7E*X#WE;E;NPMF=QW+Q$3T-IOL)"4W5E/+KFQ?18N`3KJ5(+;
MOD4:OOZ;&7K6*1?!_0;>D^-;UEJQJD7.U]=>TOM+I\GF-P+#D=CRB`BYX_<X
MEU@K`U>BNI6IE9&O9263TO1GAX4K2D^2H>Y;G;ERS33ZST3$S<7/M*_AW(W+
M?4]W4UO3ZG0FZL-H4`H!0"@.*D)6.E0!2>8(!!\X((H"%E6A"R5QE="N)[-6
MI0=>?2KZT^3E0$`ZPZPOLW4*0KQ$<]/"D\B*`ZJ`4`H!0"@%`*`4`H!0"@.2
M4+4H(2E2E*.@2`23KXA0&X.U-G4K#+4Y)/2DOW#[DGWW":\-%*X@5$9?X\O)
M\QW^A_TNWVR^\S+333;*`AI"4)'@2--?*H\U'RGC6L2Q\_OVF?=FN?><[K>2
M6;%A.?S[;69_ZGX1:8C[J6\CG6*WRV;SC;T)*@Q,EW7'Y$@02L%3<U#820%J
MUZSP7K,=&UR%R[3\M>7=R;6V-6N62?0E*BEU-\#P+^Y+X<9/Q'^&F1C:;SRU
MO3I_G,>$6TKKMQDKEIQK24IVG+NJITN*-*59^+;H=X`,22LGI#?JS_:]>O2&
M^RZ.T[7JX=.G5U<--:^C&U1[J'X]\LZ\O++GW4HZUX4IOZC?/,]T<N[JN"X'
MW><*E61&;1%/;J[YN9)B&'YPS8=Q,\L]H39]NK/"S.R7^'8I&$8/"@IO*XK;
M3S]XE/-.J4(J`.5QL*SKF5=U?)4ORTJ6[/+*<.:W"3K<?)*/,IS;<*MTCM6]
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MCS8DME:`MF3$D-*0XDC5*TD5U$9QG!3@TXM5777=3M/$KMJ]CW98]^$[=^$G
M&491:E&46U)-;ZIIIK?54/T5;+=V&Z;"?LBN]/FN6-7&)FV_>U<G-Y]AE+?0
MU8<3B)C,83#7;5'H9NURMDM<Z4LI[4(DM,G[UI7@7CS7+>J:TK&/RO&Q:P4E
M^E+]/;P322[&^D_5[^U+X;97@7X=_P`YU57(:UKDH9,K<FTK5A1:QX\E:*<H
M-W9NG-2<(OV:&X/?/95W>'+7WM[8V^U@6>[#S>[-WG(4*.ZXRU9,CPRY,;'[
MLS&(R%*7(P7.YZ;+,>4E2DVN[CCTMUQ$>#/J`L[;>_H[N2NX[WF,TA7).R>7
M]QO;[NZ[IYI;[;/ND':2_6]5BS[;_+,R9MS$F7;L'OC\N?;I5Q[,LP9'8J>*
M4*"J/I[097[VG>!VL[QFSN2]UWNX9WBN]VZW>&B6_;Z-"VWN<?,;/@&&7RZV
M]69[G;A7RS&59\6QO%L99D/-^M/MR)DLLLL-K6O@2IZSW`QGWL]RSW!]]KSO
M=88LN?9.\5W7;OM7:X;;+SHN?>;V&M[2-BTNM,(7U7/-L;R)5O\`2])PP`-?
M1TJJ7,N%`3M^V=OG="VC[@^Y#-@OV9P^ZK/R-OO$,8Q;)=ZR9RS[^X;)M^[F
MZ4>S6]IZXWQW%,_FIN$]ME#CYMY>6E)Z#1;VN(,];J]^ON\N;:7V/LQN/B6_
MNZ>:X[=+!M7M+M5=F,OS/,\KR"WR+798DFS6Q,B5C=EC3)27;G-N:(L>!$;=
M6ZH%/2;>5UV[@:S;4VY/[.7<;#D[VR9$79;=#NQ=WW;&_;TQ($^Y89MYOGL5
M9;G8)^/9M/@1Y2\;QC,+/>B[:KC(0F'VT93:UH)%7-\VU;Z@SQ>.]CBVZ^]E
MWVKV8W0V[W.VQ=[GV^N>9E(P>XVG*W+3G5KGV6S8JQ.R"TR)*;4F78[I,6F$
MLA4CIZ_K*MIL!KAW"QW!;?M=W3Y\+=_%4[^#;W;1M.+.]XG.)-Q&XLS&X<.5
M9/\`TWE9V]C_`*]Z_(<:%L^;^Q:7Z*6D](`K)NM.@%^8SL<]W@=N_P!H1@5G
MN1QS/H??KSS.MI,O2GIDX;N]@V.;;W[;_(FGATN(81>(HB2^E0[2!*?;Y*(H
M]K0/5^S_`-WSWA]VN]WN;*M$C&LHFH[ME@S[%YC#T:1B>YV&[8W/%=Q<7>0Z
MA!Z+5E=KD):5IHI@MJ'OJK))*BX@^F+C+C1Z7$E)\'A!\H/(@U8#KH!0"@/$
MY[]7GH#A0"@,37/^L9_\\D?C%5OP]E=AS5_^)GVOYSPU>8RBE)0E2UJ2A"!U
M+6LA*4I^R4I1`2//1;71;RC:BN:32B8VRK+8CL5^UVQ1?4_HW(EC@PEK7[HT
MR3Z3JEZ:=0T3IKIK6U9L/F4Y>RCG=3U2U.V\;'=6]C?13JXF+JWCFA0"@%`*
M`4`H!0"@%`*`4`H!0"@%`8GWF_5!G^_('XB;6[I_X[^R_H.9\6_TN/[Y?=D:
MN5,GFI]1>X/^H^X/^;[=_P`#37(^(_Q[?V/^8^@O@Y_2,W_<P^XC?"N=/7Q0
M"@%`*`J.1\WTQ0`\SYS[M`4H!0"@%`*`4!H#WO,CO7^*;'BR;A(:L*,?8NKE
MN:<4W'E3I,^<R7Y:$D)DEIJ*D-A8(1J2!J370Z1;@K$KE$YN=-O0DEN/&OB3
MFY7\PM:>IM8G<J;CT.3E)5?&B226Y;]^TT[J6/-10"@.#OWIW\$[^+555O+9
M^P^QFL"N9]CW!4NCD'O?:7EM[?KMCV88_+M$U^&X_>+9$E-MN*2Q-BR9C,=Z
M-,9!#;[*VG"-%`Z'B-"*Q9$(W;,HS2]E]J)+2,O)Q-0M3QYN,G<BGP:;2::W
M-,^J92>I24@G0G0#B>D$@<O-7*GO35)-+B4((X$$'Q$$'VC504H4%4`H!0"@
M.IUEM]/2ZD*'E`X'Q@\P:`MZ5:'$`KCGM!\&=`L>97)>OMT!#J0I*BDI4%#F
M"""/'J#QX&@.-`*`4`H!0"@%`/;^CZ=`2L6U//@+=!:;/C^^*_@I.G3[-`7%
M'BLQDZ-(T.@!7J>M6GA*N=`;7;9_J7;/YQ<?Z:[4/E_Q#[$=_H?],AVR^\R_
M*UR6*@D$$'0CB".8-`1XM%F"@OYDLG6%=87\SVWK"]>H+ZO5=>L*XZ\]:O[R
MY]:7G?I-;\EA5KW%FO[N'S\I^47]K%W,LJVU[QDW=+;?$<ER7`]^';GF#[.,
MV"[W\XON`V\R<SM4U-JB37(T6\RI*+G$4X$A7K3S:2>QKW/P+XCQ\S25@YER
M$,K&?+64DN:&UPDFVJM+U7UI'Y<_W1_"#4_#GQ"N>)?#^+D9&B:VYY#5JW.[
MW.35?F(2Y%*BG*2NPKT3E']`QG^S<[E68;Z=Y/&Y6XF%Y7CFV6UJX6X>7/9'
MCE[Q]F_2K3<&7,9Q*&[=84+UAR\7IM#DCLBI3<*.Z>!*:W?&/B3'TW1IQP[D
M)YE^MN/+)/E37K2V-[E5+K:X'/?V\?!S5_&OQ$QKVO8>3C^'-+<<J^[MJY:5
MR4))V;$7)1;=RY1SINMPGQ1^PAZUV=]UU]VRV5UUY:W777+1;7''''25.+<6
MJ,5+6M2B23J2:^?E.Y%44I4I3VGZ3]:'AX<I.<K-ES;JWW<*M\7ZO':>I;33
MK:F7667F%I[-;#S+;L=QL:?<UL.)4TIO0`=)'3IX*M-@HZRP^TMB0PQ(CNIZ
M'(\AEI^.X@$$(<CNI6RX@%(]%22.`\5`<DH;0UV"&F41^R[`QTM-ICF/TE!C
ME@)#)CE!T[/IZ-.&FE`>&V6BS61M]FR6:SV1J4OM9+5FM4"TMR7==>TD(M\>
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MYVSQ::;:+[Q`"GGRA*2\\M(`*U:J(`X\!0'!N/&96\XQ%BQW)+G:R7(\9AAR
M4]Q';2G&FT+DO'7WRRI7$\>-`=BT)6DI6D*2>8(H".?@?7,JU\/9JUX>1)H"
M+4E224J!!&H((\7.@*4!XG/?J\]`<*`4!B>Y_P!8S_YY(_&*K?A["[#F;_\`
M$S?15_.6/>LMMEIZFFUB=-&H]784.S;5_P!>_P`4H`\('4KR5L6[,YOA$A\S
M5K&+6$?7O<%N\YBF[9%=+RI7K;W0QKZ$1DJ1'1XM1KJZKRJUK>A9A!;%MXG,
M96=DY;I<E2'!;B#K*:8H!0"@%`*`4`H!0"@%`*`4`H!0"@%`8GWF_5!G^_('
MXB;6[I_X[^R_H.9\6_TN/[Y?=D:N5,GFI]1>X/\`J/N#_F^W?\#37(^(_P`>
MW]C_`)CZ"^#G](S?]S#[B-\*YT]?%`*`4`H"HY'S?3%`#S/G/NT!2@%`*`4`
MH!0'SE[W?_N3:/\`)]N_XE=ZZ/2/X67[Q_-$\/\`B1_7;?\`MH_?F:KU*'`"
M@%`<'?O3OX)W\6JJK>6S]E]AK/'BR9TEN)"CO2Y3Q"6H\9I;SSATY(;0"H^?
MD*EJQBJS:4>LY2%JY=N*%N+E*3V45>DV'VZV7F&\62YY3(,-+5UMLEJTPU)7
M**FIK#J!,D\6V4A2?20CJ5^^%1N5GP[N4+*JZ/;T>0[?1/"MQ95J_J,N6ER#
MY([77F6][O(?41#+,?J0PTVVC4^\2`3QYD\2HGRDURK;EO/>H6X6ERVTHQ.#
MT=B0DH?:0ZDC3TT@D#]ZKFD^:JIM;BD[<+BY9I-%L3L><2%.05]H.?8.:!8\
MB%\E^8Z&LT;WUB*OZ=**<K&V/![UV<2VU)4VHH<2I"T^^2M)2H><$`UGJGM6
MXC'&47RR7K%*%!0"@%`*`\LB(Q)'W1`ZA[U8X+'D"M#KIY:`MV7:WHX*VP7F
M]2=4`]:1^^1Q/#QB@(LC2@%`*`4`TH#W1K?(D\4IZ6_A%'1)_@_9D#Q4!<46
MW,QNE6G:.`??%@:I/C2.0'B\-`2%`*`VEVS_`%+MG\XN/]-=J'R_XA]B._T/
M^F6^V7WF7Y6N2PH!0'8AUQK7LW%HUTUZ%*3KIRUZ2-:%RE*/LMHJX\ZZ`''%
MK`X@+4I0!X<M2=.5-@E)R]IM^<ZJ%HH!0"@%`*`4`H!0"@%`*`4`H!0'4ZRV
MZDI6D'Q*'!0\QH"*>@N(U4WJM/'APZQYP#Q'EH"$<]^OR*T/D/BH#A0':VRM
MP\!H/LCP'/3GX:`T_P`\R>YOW^^VMMP18D6YS8A$<J2Y(#+[B"MUW@L!?V*=
M!X]:GL:Q%6XSEMDXKR'EFL:CDSS+UB#Y+<;DELZ:/>S'%;:5"!%5`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`Q/O-^J#/]^0/Q$VMW3_QW]E_0<SXM_I<?WR^
M[(U<J9/-3ZB]P?\`4?<'_-]N_P"!IKD?$?X]O['_`#'T%\'/Z1F_[F'W$;X5
MSIZ^*`4`H!0%1R/F^F*`'F?.?=H"E`*`4`H!0"@/G+WN_P#W)M'^3[=_Q*[U
MT>D?PLOWC^:)X?\`$C^NV_\`;1^_,U7J4.`%`5`U(`YDZ`>$D\@`.))H$JNB
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ML0NJ6Q[&0]_!N6JRAZUOJW^4A/I<#Y_%64T.FG2*`4`H!0"@(Z5;F9/4K3LW
M#R6GPG3Z]/`*\_.@+=DP'XW%20I'PB-2CV=>*3K[%`>,`\/+X?H\U`=[,5Y]
M82T@JX@%7)"?X2N`!T\'.@+ABVEEG13I[97A21HVD^#0<U<?'0$MH!IH!PY>
M0:::#R4!6@%`*`VEVS_4NV?SBX_TUVH?+_B'V([_`$/^F6^V7WF7Y6N2PH!0
M&O'>:SO<C;#;5S/=NIN$M/V>_8A:[Q;\UQV]WUFX1LSSC%,)BN6YVRY+CJ[>
M_:7,A7*7VG;B0EH-CL]2NJJE=NX'//MU\EVFR'8O&<FLLW/96X$_.K/ES^V&
M$7^[78S,5Q95^AW#%\2CW2[SX=N>DZ)D^L/RNR;X]0)%*=(,2W?O)Y^_W;-I
M-WL>QR*SENY^YMIP==F_P5DN62K5;[IF&9V+M8N!6R^6C(KGD,:WXTT7(?KC
M9;?4[U>BCIHE4&X^/.71^P61^]K9<O+]HM[]T6Q:I=B95/>BM.R>BR3YEPG6
M?1Q9UC/2'G6""A2U$$U0&OVR^ZV=;D[L[UXU>(L2#AVV^X.4X)8Q$V]RN`)_
MS#*LC,>X+W+N%]D8MD%R<;G/>LVZ'`9=C$H)7HE74!";2=X+)=PCW8/G*T8_
M&&]^U&Z>?Y/\V&:HV:XX#<,0@08EG#LM[LX$E[(76Y!?[18=0A(4DZ@@71M1
ME.\=_P!X-U\+S>^[:3L7VUFXA;V?\+87DMDOUV7G.+1\IMTAZ?=,WOL"*BSH
M=5'>0F,HR2D.)4T/1JO0"VML-_\`),Y/=M3<+5CL5>\]MWVF9$B"J:5VIS:>
MXH@6Y%H2[+=*$R%N!,SMPX4KT2GH)TI1@LW:'O*YYN!WBLJVFN-LQY>/6B];
MZ0_XKB688W<[%9MJ,TM&(8_>F,POURDXKN6<FFW)3$^-9V&W;.^$E\I2H!1I
MKL!DK9#=/<+<K-MW8U_@1;=B&#Y_GN#X\F/M[D]I9GC$<OF8[%FL[CW'(YN/
MY7,=C0%KFQ(ENBJBNK`*B$D$^CL!=N\FX&38A(VOQ;#$8Q&RC=O<!6"VG(<U
M1<'\5QKU+%,BS&=,FV^US+;.OEYN$''%Q+5;D2H@ES74]3R4H4E2C8,-7SO#
MY]C&RG>FR2Y6W#[MN1W9[M<L<7=+%"O3N!9K<$XYB>56R=%L:KF]?($^);\M
M;B72T(GO.Q[C'6VB0I*T]-`;+;:7;([[A5GN^6*4;Y-,U<D.8/?]MWD--SI#
M,5N3A>476]7VS2$QVT]0?DK[74.)"4J`H"^J`4`H!0"@*CG[!]PT!;LEE#CK
MFO`AQ?%.@^N//AH>5`="8R$G4ZJ\0/`#S@<Z`]*>8`X`$<!P'M51[@:$9G^M
M^4?W_=/Z6Y72V/P(?97S'CNJ?U+(_?2^<MNLQH"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0&)]YOU09_OR!^(FUNZ?\`CO[+^@YGQ;_2X_OE]V1JY4R>:GU$
M[@_ZC[@_YOMO[MC2*Y'Q'^/;^Q_S'T%\'/Z1F_[F/W$;XUSIZ^*`4`H!0%1R
M/F^F*`'F?.?=H"E`*`4`H!0"@/G5WO674;B6-]3:TL/XC$;8>*%!MYR/<KEV
M[;:M-%+:[9'4.8ZAXZZ/2&GC22Z+C^5+T'B/Q)A..MV9M/DEC*CZ-DI55>.T
MU2/#G]'MU*'GQ==@PZ\7\I<9:]5A$\9TI)2T4@CJ[!O@N0K3['T?&16.Y>A;
M33VLDL'2LO.:G;7+9;]IK93JXF:[#AUGL(2XVUZW.`U5.DI2I:5?[NUQ1'3Y
MM5>6M.Y?G<5-RX([+!T;%PDI+UK_`-9KYET%U+)*5$GZU7[H.OLFL&XE:*C[
M#%_BK96XA62%H0IR[6QM"2I:KA#"4I&I4?6&SP`XG0"K;C2@Z\&9<=-Y-M+:
M^\C\Z-M5>^5YS42>AO8SC52@H!0%02*#IKTD7-M,6=Z13V+Y/!YL`$GE]T3[
MUP>T?+5\;DH]AJW\.U?V^S/BOI1:,VURX)*EH+C/@?:!+?'CHL<2@@<]:V(W
M%/M(:_BW;#K)5AQ1&U>:Y6A04`H!0%-!RT&GBT&A\XY&@/.8D4GJ,=DGQ]FG
MZE`=Z4I0-$I2D>)(`'M#04!RH!0"@%`*`SW8,[P;;_;NSW?/<TQ/![4_-N4>
M/<<OR*TXY"D2!+=46(\B[RXC<AX)()2@J4`==*C[F+DY65*&+;N7)T6R,9/S
MT6SRG5V-;T70M$M9>N9F+A8KG)*=^["U%OF>Q.;BF^I59E6TWBSY!;8=YL%V
MM=]L]P93(@7:RW")=+9.87[UZ)/@NOQ9#9\:%D:UI7+=RU-PO1E":=&I)IKM
M3VHZ+$R\3/QX9>!=M7\2XJQG;G&<)+C&46TUUIGAMN68K>;U?,;M&3X]=<CQ
MA3"<EQ^VWJW3KWCQE`F,+Y:HLEV=:C(`]`/MME7@UJZ=B_;MQO7(3C9G7EDX
MM1E3ZK:H]FW88,?5=+R\N]@8F3CW<_&IWMJ%R$KEJN[O(1;E"O1S)5%SRO%;
M)=;'8;UDV/6>^90\]'QFRW6\VZWW7(I$8-F1'L5OER&I=V?8#J>M$=#BD]0U
M'$4A8OW+<KMN$Y6X>TTFU'KDTJ176Z(KDZIIF'E6,',R;%K.R6U9MSN0C<O-
M;U:A)J5QJJJHIM57$CGY&`;@HR/#I,G$LT38;C;&,NQA<NUWU5CN\&;&OEF8
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M'FE=G.,;:C]9S;45'_4W3K/9MYF6TM]@(QS:G,<`R"W8M;X<<6;!LFL=^;L-
MKU5'@(>CVB?-7!BJ4V4-ES0*((!)K+?P\O%2>3:N6XRW.4913XI52-#2O$7A
M_793AHF?AYD[<4YJQ>MW7%2JHN2A*7*I--)NB='0\<7<'9+%<ENN'Q,]VMQO
M+[KDDFXWK%D9;BUJR.=E]X3&=E2[C957%FXNY!=4)9*BMOMWAT<^%7+`SY6?
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MNVR1N4(=MO>23G&D7)"GDNR7B@.`KZ:/$RU>6/W5SOVJJ/*TVN*35:;]IB_\
MD\._R^YJ_P"?P_Y5:GR3O]];[F$TTN25SFY(RJTN5M.K2I4[TXGLKMC+R/=E
M-IP'`I%\4]<,KS]YZVX_%N3F0SH[\B?>+S)DQ[<IR]W%;2E.K4%2'E).I*N.
M.W:O7[BLVHRE==4DDV]E:[-^RC\QO9>HZ=I^'+4<_(LV-/BDW=N3C"VE)I1;
MG)J*4FTHU>VJIO.SYQV5W[Q^\XTW=-M-X\8:>@*OMH@W7'LUM<.8AU4NTOS&
M[?)G)MUP9?8+L5X%M]M:"MI0*=1DOXN5B-+)MSM.2V<T7&O95+I-72]?T+75
M.6AYN)FJU3G[B];O<E=W-W<I<K='1/?1T+;ML[NRVV`_L%:;OLE"@+D3;%+V
M@C7S#T*D3Y$LR[E;)^)&;ZY-NLN?J[(2\TN2Z^>I?4K4U?\`D<YVOS'<W78:
MKS<DN6G&M*4-=>*?"\M0_E$=2T]ZLI\CL?F+/?*:WP[OGY^9=,:5ZC.;[[;#
M3\F4^VPPPT[)DR)#B6F6&&4*>???=<4EMIIEM*EK4HA*4@DG2M1)MI+:VZ+K
M;V)>4G+DX6H2N76HVX)N3>Q)+:VV]R72WN6^A#8[DV-9A:8]_P`1R*Q9589:
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M>Y<I,9$RXO#WC#94XK0Z`Z5AM8]^_7N(3GRJKY8N5%Q=$Z+K-W4-6TK2E;EJ
MF3CXT;UQ6[;NW(6U.X]T(\[7--]$55O@<H^58M+R2X8;%R;'Y.86B$S<KMBD
M>\V]_)+5;I'9>KS[E9&I"[E!AR.W1T..MI0OK3H>(U=Q>5E9+A-8\G13H^5O
MJ>[90NAJFF7=0N:3:R;$M5M04IV5<@[L(NE)3MI\\8NJHY))U5'M1/5B-XJ.
M?L'W#0$$]]]=_"+^V-`==`*`TKW5L$FQ9A<GG$*]3O3[ET@/Z>@Z)!"I+/4.
M':1Y"B".>A!\-3V'<5RS%5]:*I0\K\0X4\34[DVO=79.47QKO7D?1UF.:W""
M%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@,3[S?J@S_?D#\1-K=T_\=_9?T',
M^+?Z7']\ONR-7-0.)X`<ZF3S6J6U[C[*=T;;R?@6TT>1>([L.\9E<%Y-)AOI
M*'HD%R.U%M##R%`*;>7":#RDD`CM0#H17#:UE1R,UQ@ZVX+E3^5_*?4/PUT2
M_HWAN,\I..5E3[R2:HU%I*":Z'RJOE-H:B#T`4`H!0"@*CD?-],4`/,^<^[0
M%*`4`H!0"@%`6QE>*8OF-K<M&56J)=82P2TA]&DF,Z1H'X,ILID1'QI[Y"AK
MIQUY5EM7[MF7/;DTS0U#3,#5;'Y;/M1N6NBN]/C%K:GV>4U*N7=GMM@EOW2P
M*E9'%2ZIV-:KF6C+AMCDA"6TH9N2D'D5:*&GO5'C4M'5I75R7$HOC_C<>?7O
MA_CX5QY.*Y9$*U4)TK%=5/;\M&6ZMIQA18<;4PXR>S4PM!;4R4<.@MD)+93I
MIIH-*RUKMWF&G*^5QY9+HI1KJ.%"IQ5[U7\%7VIH'N?80&/X3>;]TO!OU"`?
M_&RD*2'!X?5F?1<?/EX(\M73OP@NLUL32\G+]9KDL_6?3V<3-UAQ.S8^D*BL
M%^9IHJX20E<GB-"&M!T1T'Q)`)\)-:<[L[GM;CI\33L;$VVU6Y]9[_)P\A<M
M8S>%`*`4`H!0`\00>(/,'B#YQX:=F\;]Y!3K#'DDKC'U9T\TI!+*SY4^^02?
M".'DK+"ZX['M1'7]/MSK*UZDOD?H+3DPY,-70^TI&NO2OWS:_P"`L:A7NUL1
ME&6YD3=LW+,N6XFOF/-53$*`4`H!0"@%`*`4`H!0'S@W$E[$X[W\!>N_A;(4
M[8JX[%VR'W=+EN%:[E>=H;5E#,]E>>QYD*/'EVU.1/3DRSU/-J*5+:4H#J84
M.TPXZG<\+NWX8DUJD<EN^H-1NN-%RM-T=*4W;]J3WGS7XDGX)POCF\KXVVHW
M/!5S1H1TJ63"<\&%U23R8N*3AWKFKCK.+HW%O?!GU"[OFY/=;Q3NOWC<CN^0
M8N.=WC`!N;D:66K3><?@$XY,NE\R:=;F<D")[]MNTD%<-XJ+;C+K:$=/3V:.
M+U7"UJ_K4</5'S:K=[N.]2?K445LW-?I+?6K?%_1_@3Q'\,]+^&E[Q%X#C#'
M\`X*S+J]2Y:C[ISNWG%7?6E&<O8G5IJ48JE.5?$[N4[B;@[;]Z+9#O!;C[?;
MBX79>^_=]R\<SG<#+!!9P+.[]N%D#^8;0.X>XU-?FMM6*.PQ#(EM,%Q"RIKJ
M3J1Z-XCP\7,T3)TS$NVKES3HVY0MQ]N$8)0N*7&JJ]GE/C?X-^(=>\/_`!,T
M?QSXAP<_#Q?&5W+LY.3?Y5C9%S+N=_A.PU)R7)ZEM<\8U3;C5-FWG[5#;C)M
MV.\=W#<`P?(E8CN!=W]\)F`Y$A0:7:\WQJTXUE&+.+=U"F8\B^V5AEU8]XAP
MJY`@P7@?+L8.D:GEY,>?%CW2FN,).49?(ZGJO]SWA_4?%'Q"\$:)HM]XNO7/
MYC+&NITY,BS"S?L]B=RW&+?16NZJ<W^R>S[)MT-S._7GF>8X<0SF_;K;=KSO
M&%I+;MFRZV8S>;+DT);2D)<8`O-N?6A!![-*@G4Z:G!X[QK.%B:;B8L^\QHV
M)\DN,7.+3\S53?\`[6]=U+Q)K_C77-<Q_P`IK-[4L7\Q:=?=WX6[D+T=M*+O
M8SHMRK2N\U\M5S[H&*=Y;OS,_M*;+9)>YMVS^7/VSN6Y]BO][M%TV,5!?;Q:
M!M*NWQY*8MP3$[(-F&IM_7H2VXEQMX"7N6]>NZ1ILO"$I+#5I*YW<HIJ]7:[
MM=OD==U>!P6'D_"G3OB'XTM_W#6;4O$<\Z4\2>7;O7(2T[E?<1PN1/EFHTHX
M4EN49*49F_O?`GX)<_V7.[-PVQM[EKVVE=W>R+P6UR+=,M#]NQ1+^.-V2`_;
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MY/+$9+9IUKR)>[3N2?\`J?C`3(M5T8<&+M6KYP,,E#P+G8I=\)37K<)Z2_%^
M)&4<C^;O$CRM-=UR\DFTUOYEMVKBMA^?F3:\?_\`Q[\07+%W25\//_(+JNVY
M0N_GN]_-66G"2]SR5[O?M45))[4?:+]IIT?_`.9VYW6/0_P5LR=-0!^M^`Z=
M))Z=>`TKSOP97_S&RZ[>]O/_`.F9]@?W(4_^.>H[J?E-/_\`S8R./[,>Z;5R
MMOLQ@87?^ZW?,N9?Q&5E1[L6&WK#HD6S.6-,?'V=PFKW'9=NN6-W%JX!<AHE
MHZJT`U-/&<<U9=J63'-C9]91_,2C/UN:LN[:I2%.6D7U;2[^VV_X:N:#EVM(
MO>&KVJJ5B5[^46+EB,;?=N-K\RKBK*_S][ZT6X[TCXJ;\XFY<MV^^!D]XP[!
M+5MM!_:`8E8LZ[QR84NY;M[&MSKN_+8E6")$D0PSA]W3&4F4^MP@3.A/3U*2
MI/HVF9"CIV#8A=N2S):7*4,?=:O-)*DF]\UO2X;:[#XX\<Z3<R/%7BG4LO$P
MK7AZ'CBS;R-52<LW3XRN2ES6XQ:]S-Q:DZ^W14JTU]X?VD>[\O;;NAY5;\)D
M.WK.-\UV#8[;!NUOMR;E?[IN6@VYZ99RTXGU^4YC`DN-J;/2MQULZZ*KR_P?
M@1S=?MO)7+C8U;URJHHJV]B?#UTMF_8S[@_N'\5W/#OPHRL?1Y=]K&MRMZ=A
M\C3G=GE^JY6Z>TW9YG%K>Y1?2:P_LM+Y.VGS[?\`[H&1X1F^U*+&O'MZ=K,`
MW,5;DYA$Q#(;9;[!EI<%KESK;(CN9%!:EH4PZM($E75HH*`F_&]N.=BXOB"W
M=MWW).U=G;KR\Z;<:U2:?*Z;>'8>:_VR:A>\-:WKOPIU##S=,5EVM0P\;,<>
M_5F["-J_7DE*+CWL83]5NG.Z[:I:K]X+N[;@]YKOM]_K;?;3:O:#,KW=+3L-
M%D;D[EWU=DO>RB9.*6-Q&4X0F+!ES;A<;@U#<9DMM=*NS;0-%A729[2]6Q=&
M\.:7EYE^_;MUO^[MQYHW:2?JRZ**O2F>7^./`.N_$?XS^.=`\.Z7I>9F3AIJ
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M0BCZBUQ1]*E1S]@^X:`@GOOKOX1?VQH#KH!0$+?\=L^3P%VV\Q1)8)ZVEI/1
M(BN\NVBO@%3+FG`Z:A0X$$5DM79V9<T-_P`_::F;@XV?9[C*BI0Z.*?%/>F:
MQY?LY?+)VLRQE=^MJ-5J;:;";G&;&I)<CH)3)2D<U->EXTBI>QG6[FRY2,S@
M-2\+Y>'6[B5NX^^GZ:XU73Y##A!25)4%)4E12I*DE*DJ2=%)4E0!2H'@0>5;
MR=54YEIIT=4^O84JI04`H!0"@%`*`4`H!0"@%`*`4!Z(L25.?3&AQW9+ZSHE
MME!6H\-=3I[U(\).B1XZME.,=LMB,ENU=O2Y+47*;Z%_C8NLRC9]M@I`=ODE
M:%D#2'"6D%`/$=M(*5@J\B1[)K1NYM'RV]QT>+X?]7FS)-2^K%KY7M%XVV"6
MR[9)*EK2-3$FJ3JO3P-24A`"B.&BAQ/UPJEO-JZ7-Q3+\/I1YL-MR^J_HE_D
M8)S;;/.<[@QL7QG'ILZ[_/<%Q]"TB-&@QT-2TN2YTU_ICQXK96/2*CU:CI"B
M0#*XV9C8\G>N2I#E?E.*UO0=7U:S'3L&Q.67WJ;3V**Y9>M)O8EUU-AMG.YO
MBN$R(.1Y]*9S+)(RFY,:V(:*,7M<I&BD*[%T!^\/QW!JE;H0UU#4-G@:C\[7
M+M].UC+DLOI_2:^@ZSPQ\+]/TF4,[6)1RLZ.U1I[J,N--\VO]5$GN1ND23SY
M^P/:`Y`"H$]4ZRE`*`4`H!0%1R/F^F*`'F?.?=H"E`*`4`H"BE)2-5$`#PDZ
M4!X'9AXAH</LR-?_`*0>%`>!2BHZJ))/A/$T!2@+<R#$[)DK>EPBA$E*=&I\
M?1J8W]B"YH0\VG[%8(\U9K=^Y:?JOU>!'YNF8F='WRI=Z)+8UZ3"L_:;(6)@
M:M[L.=#6K5$M3R8RV4D\!(85U*ZD@_[,K!\G*MZ.;::K+8SE[GAS-C<<++C*
MT]S;2\Z,B8]MI9K*CUF?T7BX!"U!;S>D)A703]PBJZ@M23R4YU'P@"M:YE7+
MCY5LA4F\+0L7%CWM[WMZG3[*?4NHMH^UIX.`'#Q```<*S5JC4HEL6XI52@H!
M0"@%`*`4`H!5`<'&T.I*'4)<0>:%CJ2?8/*JIM;MY248S7+-)Q+;FXZ#JY!5
MT\SZNX?1/X-P_N!59H7FMDB+OZ:O:L-TX/Z"UW6G65EMYM32QS2L$'V/`1Y1
MJ*V$T]J(J4)0?+-4D<*%HH!0"@%`*`4`H!0&R>$66RW_`&_M=NO]ELU_MXF3
MWA`OMJM]X@A],U[I?3$N4:5'2\`>"@GJ\M1>1=NVLISM3G"=%MBVG3AL:.UT
M["P=0T:W8S[%F_8YI/EN0A<C7F='RSC)57&E3(;EOMKMO-H=MEN<M!B^HJM#
MD"(NU*A`%(AFV+95!,0)X=EV?9Z>"M53FI]XI25RM>:OK5XUWU)J6-C3Q_RD
M[5N6*X\K@XQ<.7ZO(URTZJ4ZCH>LMDDQH,*39+-)AVMR.]:X<BU6]^):WHB>
MB*];(KL=3%O>BHX-+92A38X)(%7*[=4G-2DIRWM/?V\2R>%A7+<+-VQ9E9M-
M.$7"+4''V7!-4@UT.-&CMD6VVS)<.?,MMNF3[:IU5MGRX$23.MJI`"9"K=,?
M:7)@JD)2`LM*05@:'6J*Y<C%PC)J$MZ3V/M1?/&QKMZ&1=MVYY%NO).48N4*
M[^233<6UL;BU7I*QK;;(,B=+@VRW0I=T>3(N<J'`AQ)-SDI!2)-QD1F&GI\@
M!1T<>4M?$\>-)7+DHJ,Y2E%;JNM.I<$4M8N+8G.[8M6H7;KK.481BYM=,FDN
M9];J^L\EUQ[';ZY">ON.V"^O6U17;GKW9+7=WK>LJZ^N`[<8DER$KJ&NK92>
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M\0V`EM%Z*HI-W0VD:)$GM0D<M*IWUU))3FE'V=K]7LX%SP,"7>5L6/?_`(ON
MX^]IN[RJ]>G1SUIT'NC1HT.,Q#A1HT*)%:2Q&B0V&HL6,PV.EMB/&80VQ'9;
M2-$H0D)`Y`58VY-RDVY/I>\SVK5JQ;5FQ&,+$52,8I*,5P26Q+@E1+@<9<.%
M<(K\&XPH=Q@RFRS)@W",Q-A26E$%34F)*;=CR&B4CT5I*=1RI&4H24H-QDNE
M.C\Y;>LV<FT[&3"%RQ+9*,XJ49+@XR33\J.UAIF*TS'BLM18\9M#,:/&;;CL
M1V6DA+3,=EE*&F&FD@!*4@)2``!H*.3E+FEMD]Y="$+4%;M)1MQBDE%422W)
M);%3@J$5_AS&_F^19_\`#>._,\N0J7+M'S%:OFF7*6XAY<J5;!$$&1*6\VE9
M<6VI94D$G4"LG?WN=7.>7>K9S5=:<$^A&K_+=-_+2P_R^.L2<N9P[JWR.5:\
MSAR\K;>UMQJ^)[9MNMMRAKMUQMMON-M=0VAVVW&#$G6YQ#*D+9;<@RF78CB&
M5MI*`4:)*01IH*LC<N0GWD&U/BFTZ\:K:;%_'Q<FR\?)M6[F.Z5A.,90V;ER
MM.-%T*E#R6O'\>L7;&Q8]8;$9/9^LFQV6V6?UGLNKLO6?FZ+&]8[+K/3U]73
MJ=--:NN7KUVG?3E.FZK;IYVS#BZ?I^!7^7X]C'YJ5[JW"WS4W5Y%%NG14+Q_
M'76KI'=QW'W8]\=#][CNV2UN,7J0DA2)%Y97$+5UD)6D$+D!Q0(U!U`JO?WJ
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M6[T\FW;MQR;E.>:C%2G3=SR2K*G1S-T6Q'K4E*DJ0M*5H6E2%H6`I#C:TE"V
MW$*!2M"TD@@\"*L[#*U&47&23BU1I[J<&>6!;[=:HC4"U6^!:H#'7V$"V0HM
MN@L=:RXL,0X;3,9D+<45'I2-2=3QJZ4YSES7&Y3?2W5OM9BL8^/BVE8Q;<+5
MB.Z,(J,5V1BDEY$>NK3,5'/V#[AH"">^^N_A%_;&@/#+G0K>V'9TN/$0=>DO
MN)1U:`'T4D]2O8!JJC*6R*;9CNWK5E<UV48KK9',9+8)"PVS=X96HZ!*UJ:U
M4?`"ZE"?W:O=JXE5II&"&?AS:4;D*LF^>A'$$:@CB"/&".!%8^TVJ[*E=3SU
M.M"I866;<XYEH6])CF!<R-$72"$MOJ(][ZVWH&IB0>?4`KQ$5LV<J[9V5YH<
M&0^I:'@ZDN:<>2_39*.^O6MTEU?*:PY7MMD>)E;[[!N-K3KTW2"A;C*4Z\/6
MVO2=B+TYE7H:\E&I>SEVKVQ-*7!G`ZEH6=IK<IKO,=?IQW=C6^+XUV&/ZVB$
M%`*`4`H!0"@%`*`4`H#DE"EJ2A"5+6HZ(0E)4I2CR2E*022:HVDJLJHRD^6*
MK)]!D.Q;>SIP;DW9:K=%5HH1P$JG.I.A&J5:HCA0^RU5Y*TKV9&.RWM9.X6A
M7KU+F5ZEKA^D_-N\IEVVVBWVA@1[?&;81H.M6G4\Z1]<\\K[HXKSG0>#2M"=
MZ=SV]YU&/C6,2')CQ45\K[62C;;CJPAI"G%J/!*023[0X#R\JQ&RHRD^6*JV
M7)#Q\^BY.5IX>P;5^XXX/!Y![=6NXDFD2%K!Z;K\B+MA*,,@1M&DI3H$)`""
M!]DGZ[V>-8FV]Y(1C&"Y8I*/47$Q<6G-$NZ-+\!&O9D_PB=4>S5"XD?+X_H]
MF@%`*`4`H!0%1R/F^F*`'F?.?=H"E`*`4!XW9B$<&_34/#]:#_\`E0$>XXMP
MZK43Y/`/,*`ZZ`4`H!0"@.*_>.?@W/M%55;UVELO9?882J06XYE[Q52@H!0"
M@%`*`4`H!0"@%`=$B-'E-]G(:2X..AY+3Y4+'I)(I%RBZIF*[9MWE2XD_G\Y
M:DZP/,:N0R9#7/LCH'D#R:<'!^[Y*V874]DO:^0BK^G3@G*T^:/#I_S+?(()
M!&A2="#P((\!!X@UE(ZC%"@H!0"@%`*`4!M+MG^I=L_G%Q_IKM0^7_$/L1W^
MA_TRWVR^\R_*UR6%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`\LV="MD5
MZ?<9<>!"825/2Y;J&&&TZ'BIQ9`UTY`:D^"KHPE.7+%-R9CNW;5BV[UZ2A:6
M]MT7^.HPW>=R([J5_P"'DB0V_JXU<GT$-J0OTD+C,*"5*!2K4*7IYJVH8S3K
M=\WI(2_KD'%/"]9->TUL[4F8PES)4]Y4B8^[(>6=5..K*CY@#Z*$C7@``!6R
MDHJBV$#<N3NRY[C<I=?T'F^G52PNBRY;=K-TLI<];A<`8<A2B$CC]X=XK9/'
MD-4^2L<[4)K=M-_$U+(Q/57K6OJOZ'T&7;-D]JO8"67NPE::JA2"$/:GX%7O
M'T_P>/DK1G:G;VO<=)C9^/E;(.ESZKW^3CY"X:QFZ.!!20%)4"E25`%*DJ&B
MDJ2>"DD<P>!H'1JC1B#+MGK%?B[-LQ38;HH%12TCJM<EPZ<7HJ?2CJ4>:FM!
MXTFMZQFW+>RYZT/E.9U+PQB9=;N)2SD=7LRKQ71Y*&M&18E?\5DF/>8#K"5$
MAB8V"[!D@'@6921V9)'UIZ5CP@5+6K]N\D[;VG!9NG9>GS[O*CR\'OB^Q^DM
MNLQHB@%`*`4`H!0%"=.-`VEM>XN^Q87=[T$/*1ZA!5Q,F0@A3B?]W9/2MWJ'
M(G1/EK6NY-NWZN^1*8>DY.7ZS7)9XOI[$9ELN,6FQH!BL=I)TT7-?T7(/C[-
M6@#*#XD@>4FHVY?G<V/<=7B:=BX<?=JMQ_I/:_\`(N#GP'$\!P&IU\PYDUAH
MS?["=A6*0_TN228S//I(';+'B"3J$`Z\S5DII;%M9MV<.=SUKFR)=4:+'AHZ
M([:4#ZY1]):_*M9&IK'*3EO)2W:MVE2VJ?.>BK3(<T<_8^F*`[:`]4>8]'/H
MJZD>%M7%/L>(T!-,367]$Z]FYRZ%$<>'UJAP4/:-`>R@%`*`4!4<CYOIB@!Y
MGSGW:`I0"@(^8]R:2>&G4O0^^X\$\#RTH"/H!0"@%`*`4`H#BKWB_*A8_P#L
M-56]=I26V+[#"9&A(/,<ZD%N1S&\I52@H!0"@%`*`4`H!0"@%`*`4!;&0P4A
M`G-`!06EM_\`?!1(0YPX=6HT/C'&LUJ>WE>XBM1L1Y>_BO6K1^7I+4K8(@4`
MH!_TGV!S]J@,59?NYC>,*<AQ5B^W5'HJBP74^K1UZZ$2YR0XTA2=>*$!:_&!
M6Y9P[MW;+U8<?\B#S]?P\*L+?O;ZZ$]B[7_C@,0W;QO)RW$EJ%BNR]$B)->2
M8SZSPZ8DXAMI9/V*PA7BUI>P[MK:O6AU>@:?K^)FM6[GNK[W)O8^I/=YS*OB
M\NFGEUY:>/6M,G=YM/MJA2,,M74".IV>XG4::I7-?Z2/&"!41E_COR'>Z%7^
M66Z\9?>9?5:Q+B@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0%"0E)6HA*$@J6M
M1`2A*>*E+4>"$I',G@*#KZ#!>;[[8[CA>@X^&\DN[?4A3C+O3:(;@.A#\M&I
ME.(/-#7#]^*D<?3;M[UIOEM_*<CJWB[`PG*QB>_OK97=!<:OI[$:\O-;@[KS
M1.N\MU-M"SV+DA*XUHBI)T4+=`1P?6`??`*)/OEU).>+@1Y;:K<^5]K./C9U
MOQ)>5[)E)6-Z;JH17^F/3V[^LRHK$9=N@Q&XKOK[<>*RTI24%M[[DVE/7V74
ML%)`Y`ZBHY7E-MM4;.K>EW,6Q"-I]Y&,4NO8J;B!(*20H%)!T(4""".8((!%
M7FEN='O*54"@*I44D$<%`@I4"04J'$*20000?#5.W<-VU;R_+'G<^`$1[DDW
M"*G1(=*@F8TGEP</HOA(\"N.GAK!<L1DZQV/Y"7Q=7NV?5O^O;X]*])E>VW>
MW7=GMH$E#VGWQHD)?9)^M=:/I)/'GQ!\!K4G"4'229T5C)LY,>>RZKAT^8DJ
ML,YYY<2+/C.0YT9B7%>!2['DMI>96"-/2;6"G4>`\Q58MQ?-'9(LN6K=Z#MW
MHQE;>]-)KY3`>6;',/%V=B$@1G#U+59IKA,=9'$)ARSJMGAR0YJG]\*DK&H.
M/JWELXKT'&ZCX2A*MW37RO\`Z<MW_"^BG!^<UXN5KN-GEK@W2%(@2V]>IB2V
M6U$`Z=39]ZZ@Z\%))!J4A<A-<T'5'$W\>_BW':R(N%Q=#/!5YA%`*`4`H#+.
MWN/0I$=R]3&4274REL1&G4A;;(9">MXH.J%.J6K0:CT0*C\R\T^ZCPVG3Z%@
MV9VWF7$I2K2-=RIO[69;J.>UG3[R2AVJ5,T4$AIG4:O.`@'^`GWRSI[%6N44
M;%K%NW=M*1Z^DNR';(L+BA':.Z:%YP>G_P#(`=$#S<:Q.<FB3M8UJUM2]?B2
M!.M6FP*`4!S1S]CZ8H#MH!0"@)FW2%J465DJ!05H43KT])`*==>1UH"7H!0"
M@*CD?-],4`/,^<^[0%*`4!#2?O[GG'VHH#HH!0"@%`*`4`H!]'T<J`QS?[([
M%>=EQVU.175%Q70.,=:CZ06`/O95J4GV#6Y:N*2Y>D@\O%E:DYQ5;;^0M:LQ
MI"@%`*`4`H!0"@%`*`4`H!0$7>?ZLE>1+>G_`&S0J^W^(C5SOX2?53Y_\RP:
MVSG10"J@U1WCS;(4Y!<,7C3E0;1%9B=;4/J9>F&3%:D+]:D)(=6V"[H$`A.@
MX@ZU+X./:[M7FDY/<<+X@U'+_-RPX3<<>,55*J<FTGMZNHP+YN%2.U[SF!IK
MPTU\G`_N&E:#?LWHV=[N\_,<HR^U8;ZT[*QZ6F9VTF>%O"U(BQ'9*O5)2SVA
M)#)2&=2./UO.HC4XV+5F60DN\7#I.S\(W=0S-2MZ<I-XTZUYMO+15V/R4H?6
M.%$8M\.+`C([./#8;CLHX:A#20D:D`:J.FI\9-<?*3E)R>]L]_M6H6;<;-OV
M(JB/35ID%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"H!/`4'SF,\VW6Q3"4N,29/
MSG>$CT;-;G&W)"#IP]=>U+,)'$:]1Z].236YCX5[(VI<MOB_HXD%JGB#`TM.
M$GWF2OT(M5_XGNCY:OJ-0,VW8RO-2N/(D_-EG)/19[<MQMA203T^NOZAZ<O3
MGU:(\214WCX=C'VQ5;G%_1P/,]7\1ZAJK=N4N[Q7^A%M)_:Z9>79P1-;6XQ9
M[K&F7:Y1A,>AS1&C,/:*BHT80\75L>]><ZE\.K5(`Y>$:^H7[D)*W!TJJU\I
M*^%M-Q,FU/*R(\TH3Y8I^RMB=:=+,]H]'I2D)2E.@"4@)2E(\``T`2!X*B-^
MU[SO*+8DDDN!,LG[DWI]@C]Q(JY;#,MR(:]6N'*B29"VDID,L.NH>1Z*R6T%
M6CFG!P'I\/&KH2:=.@U,S'LW+<KDDE<C'>8N]WP^?PUM'.(4`H!0'='DR(CR
M)$9YQAYL@I<:64J&G@U!XCR<C5&DU1EUN<[<U.W)QDNE&3;)N$?0CWMK7D!/
M8''Q:R(_`'RJ1IYJU9XRWPW\">Q=9=5;RUL^LOI,FQY,:8RB1$?:D,+`*7&5
MA:3PX@D'5)\8.A%:K33HR>A.%R*G;:<7P.ZJ%Q#WO'[-D<14*]0&)S)UZ%+'
M3(84>'7&DI^[,*'[T^<&K[=R=J7-!T-7+PL;.M=UDP4H?*NQ]!K?EVRMTMH=
MFXRZN\0QJLP'`D71A.O$-]/2U-0D>+I7I];4M9U"$J1N[)<>@X;4O"N1CIWL
M%][:6WE?M+LX_.80<:<9<6T\VXRZVHH<:=0IMQM8YH<;6$K0H>(@5()I[5N.
M3E&4).$TU-;&GL:?6N@X54M%`*H]JH#83;*%)F8\E+#94!/FZN$:-)]-`)4O
MEP\FM1.:UW[;W'<^'+-R]I\5;W<\MO1OXF985DC1M''M)+PT(*DZ-(//T$'7
M4@^$U'N;Z-QUEG#MV_6GZTB9^E5AN"@%`*`4!S1S]CZE`=M`*`4!(VW^4#\$
MO[:@)^@%`*`J.1\WTQ0$B1:-3]TNO,_[&%_W]`4TL_PEU_[&%_W]`-+/\)=?
M^QA?]_0$6^FP]LOJ=O75J->F/`(Y#EK)!Y4!T]./_"WOXO;_`)50#IQ_X6]_
M%[?\JH!TX_\`"WOXO;_E5`.G'_A;W\7M_P`JH!TX_P#"WOXO;_E5`.G'_A;W
M\7M_RJ@'3C_PM[^+V_Y50#IQ_P"%O?Q>W_*J`KTV#0_=;UIH=?XO;O>Z>EK_
M`!K7ITY^"A1TZ=WR>@Q_>T;>E]73(R)$CJ^ZFW0[2XUU<=>M+L]IKK\?0?/6
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M+IGULC]6'[94,[9:C_S+<'\QXQ_J"E;_``AYWZ`XZ93VLC]6'[9J1NC$[OZL
MWNQNU^WM:GEJW=LW;,2V^D0@/4&.R[)V9FL:0HEO3JU0-%:Z:CC4QAO._+QY
M(V>7KE*OR1."UF'AMZC<[^YGJ[2->6W9:]E4HW=3^0Q_ZGW;O_Z+?S_DS;7_
M`%Y6S74?JV/UI_LD9R>%?^KJ/_I6/^\2EHB=V%,QOUZ_;Y.,ZC03,2P!B*%>
M`OJA9K(?4C7P``>/A5EQZER[(V?)*7TQ,MB'A/O5SW-1:KTV[*7EI=;-Q-EV
M-H4YQ8%8Q=-P'G@Q<O46YMAQ&-:%(^;9/:]3UNR.6^@AK4IZ6U:JT!T&IJ%S
MGD_EI=XH4IT.5=_6DCO/"\=&6K67@SR7<]:BE"VH^R][C-O=U=INSTV;X:[?
M%H7RNH`]6'39OAKM\6A?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM\6A
M?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM\6A?*Z`=-F^&NWQ:%\KH!T
MV;X:[?%H7RN@'39OAKM\6A?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM
M\6A?*Z`=-F^&NWQ:%\KH!TV;X:[?%H7RN@'39OAKM\6A?*Z`=-F^&NWQ:%\K
MH#&NYC*EV=9M]QS^/;PVOYQ1A]EQN9=U-:'K/:7"_P`&6ECHYB,DKTUU.E;>
M&[?>>LH.==G,VE\B:\Y!Z[',>*^YED1L4]?N8PE.G_%.,J?9VFESD;9OM7.U
MO.[G;=HKM>UQK"NU[7J/5VG7EG:=IU<^KCK4_7+IL5KE[94\GJGEW)HM76YG
M<W3[NU7RUN5\^TZ_5ME_[9W:_P"6L)_U92N7PM>>7[)BY-`_ZF;_`.G:_P"X
M9SVM9VV39[B+3<<^=8^<CVJKI9<:CO!WU1G@VF'?Y+:F^C3B2#KX-*BL_O>]
M7>**?+T-OI?%([CPNM/6%<_*2ON'>[>>,$Z\JW<LI*GE,EAO"]>$S+/S99?%
MQYW;3E6CZW4=+[KC/S+TDC';Q#LAI+RDIU/3U6ZS@Z>Q="--:KZW49EW=/TO
MD])PG-X=ZC,[27E(;]5D=91;K,5A'9*ZB@*NB4E>G+4@:T7-5;MYCO\`==S/
MF<N7EX+TF+BSMQJ?_,<]Y_V-C?Z>K:][PCYWZ#G4L#ZU_P#5A^T4[';C^T<]
M_,V-_IZGO>$?._0*8'UK_P"K#]H=CMQ_:.>_F;&_T]3WO"/G?H%,#ZU_]6'[
M0[';C^T<]_,V-_IZGO>$?._0*8'UK_ZL/VAV.W']HY[^9L;_`$]3WO"/G?H%
M,#ZU_P#5A^T.QVX_M'/?S-C7Z>I[WA'SOT"F!]:]^K#]HN3&V<8]<'S#<=P^
MTU';:6;&_4^CA_*^J_=AT^?TO%QK'=K3WBC3M?H-S"5OO?\`VDLCF^S&GE]:
MAF5*+!TIZY-[*]!U$0K<D%6G$A(N"@./@U-:+I79N.H5:>MO.71CWY1?/B=N
M^74*@(Q_P2+Y\3MW[G\>JCIT@P]NDC9HL$9/)O:;T4?Q95GA6E5]2/K2XD7!
M#*F`?!)(2?`:W\/\U7W7L=>XYCQ#_).3_P#8?Q5-G)3O/+T4^T:Z^K[/?VON
MG_RYAO\`JFI:N3PM^>7H.)Y=%^OE_J6_^X/5]GO[7W4_Y<PW_5-*Y/"WYY>@
M<NB_7R_U+?\`W"<QUG8I-T8-VN.XS\77WMRLV.Q8`7J-#+7;+],F*:\8"0/&
M=*Q7GF<GNU!/J;K\J1M82\.K(7YF62[?^J,5&O7R2E*G8;9PT81ZG&^:)-Q%
ML[)'JGS="LYA]GIP[$M7`)\_A\=04^?F?/7FKMK4].Q^X[E?E>7N.CEI3KW'
MHZ,9_*<@^(VS](U:91T8S^4Y!\1MGZ1H!T8S^4Y!\1MGZ1H!T8S^4Y!\1MGZ
M1H!T8S^4Y!\1MGZ1H!T8S^4Y!\1MGZ1H#L0C&N.DG(/!_P"!M@\?_P"P-`<^
MC&ORF_\`Q*V_+Z`=&-?E-_\`B5M^7T`Z,:_*;_\`$K;\OH#W048]VX[.1?"K
MLU>_AVX)TZN/%,XG6@)GILWPUV^+0OE=`.FS?#7;XM"^5T`Z;-\-=OBT+Y70
1%0FS<?NUVY?DT+QC_>Z`_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
